

FILE 'HOME' ENTERED AT 09:11:43 ON 10 NOV 2009

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.22

0.22

FILE 'REGISTRY' ENTERED AT 09:11:53 ON 10 NOV 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 8 NOV 2009 HIGHEST RN 1191799-54-8

DICTIONARY FILE UPDATES: 8 NOV 2009 HIGHEST RN 1191799-54-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10577334.str



chain nodes :

12 49

ring nodes :

1 2 3 4 5 6 7 8 9 13 14 15 16 17 18 19 20 21 22 23 24 25 26  
27 28 29 30 31 32 33 34 35 36 41 42 43 44 45 46

ring/chain nodes :

10

chain bonds :

12-49

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 13-14 13-18 14-15 15-16 16-17  
17-18 19-20 19-24 20-21 21-22 22-23 23-24 25-26 25-30 26-27 27-28 28-29  
29-30 31-32

31-36 32-33 33-34 34-35 35-36 41-42 41-46 42-43 43-44 44-45 45-46

exact/norm bonds :

5-7 6-9 7-8 8-9 12-49

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18 19-20 19-24  
20-21 21-22 22-23 23-24 25-26 25-30 26-27 27-28 28-29 29-30 31-32 31-36  
32-33 33-34  
34-35 35-36 41-42 41-46 42-43 43-44 44-45 45-46

GL:['1'],['2'],['3'],['4'],['5']

Match level :  
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS  
 11:Atom 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom  
 20:Atom 21:Atom  
 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom  
 31:Atom 32:Atom  
 33:Atom 34:Atom 35:Atom 36:Atom 41:Atom 42:Atom 43:Atom 44:Atom 45:Atom  
 46:Atom 49:CLASS  
 50:Atom

11 STRUCTURE UPLOADED

=> d  
 11 HAS NO ANSWERS  
 11 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s 11 sss ssm  
 SAMPLE SEARCH INITIATED 09:12:12 FILE 'REGISTRY'  
 SAMPLE SCREEN SEARCH COMPLETED - 22304 TO ITERATE


9.0% PROCESSED 2000 ITERATIONS 3 ANSWERS  
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
 BATCH \*\*COMPLETE\*\*  
 PROJECTED ITERATIONS: 437137 TO 455023  
 PROJECTED ANSWERS: 322 TO 1016

12 3 SEA SSS SAM L1

=> d scan


12 3 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 1H-Benzimidazole-2,7-diamine, 1-phenyl-N7,N7-dipropyl-N2-(2,4,6-trimethylphenyl)-  
 MF C28 H34 N4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 3 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 1H-Benzimidazole-5-carboxamide, 6-(3,5-dimethyl-1-piperazinyl)-N-1H-indazol-6-yl-2-[[2-(trifluoromethyl)phenyl]amino]-  
 MF C28 H27 F3 N8 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s 11 sss full  
 FULL SEARCH INITIATED 09:12:50 FILE 'REGISTRY'  
 FULL SCREEN SEARCH COMPLETED - 448427 TO ITERATE

100.0% PROCESSED 448427 ITERATIONS 586 ANSWERS  
 SEARCH TIME: 00.00.08

L3 586 SEA SSS FUL L1

=> file capl  

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	166.36	166.58

FILE 'CAPLUS' ENTERED AT 09:13:01 ON 10 NOV 2009  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USABTERMS" FOR DETAILS.  
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.  
 The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Nov 2009 VOL 151 ISS 20  
FILE LAST UPDATED: 9 Nov 2009 (20091109/ED)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2009  
USPTO MANUAL OF CLASSIFICATIONS THE SAURUS ISSUE DATE: Aug 2009

Ciplus now includes complete International Patent Classification (IPC)  
reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate  
substance identification.

During November, try the new LSUS format of legal status information  
in the CA/Ciplus family databases for free! Complete details on the  
number of free displays and other databases participating in this  
offer appear in NEWS 10.

=> s 13  
14 51 13

=> s 14 and (pr<20041027 or prd<20041027 or ad<20041027)  
25028355 FD<20041027  
(FD<20041027)  
4549516 PRD<20041027  
(PRD<20041027)  
5072655 AD<20041027  
(AD<20041027)  
15 36 14 AND (FD<20041027 OR PRD<20041027 OR AD<20041027)


=> d 1-36 ibib hitatr

15 ANSWER 1 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2009:576501 CAPLUS <LOGINDID:20091110>  
DOCUMENT NUMBER: 150:515173  
TITLE: Preparation of fused azoles such as 2,5-disubstituted  
benzimidazoles, benzoxazoles and benzothiazoles as  
kinase inhibitors  
INVENTOR(S): Di Pietro, Lucian V.; Harnange, Jean-Christophe;  
Askew, Benny C., Jr.; Elbaum, Daniel; Germain, Julie;  
Hagood, Gregory J.; Kim, Joseph L.; Patel, Vinod F.;  
Potashman, Michele; Van Der Plas, Simon  
PATENT ASSIGNED(S):  
SOURCE: Angen Inc., USA  
U.S., 95pp.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 7531553	B2	20090512	US 2004-804915	20040319 <-
US 20040209892	A1	20041021		
AU 2004223827	A1	20041007	AU 2004-223827	20040322 <-
AU 2004223827	B2	20060306		
CA 2518909	A1	20041007	CA 2004-2518909	20040322 <-
WO 2004085425	A1	20041007	WO 2004-US8809	20040322 <-

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,


CH, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LF, LS, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI,  
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY,  
TC, TM, TN, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: BW, GB, GM, KE, LS, MW, MZ, SI, SZ, TZ, UG, ZM, ZW, AU, AL,  
BY, BG, CZ, DE, DK, EE, FI, FR, GE, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI,  
SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, HR, KE, MG, MN, MU,  
TG, TO  
EP 1438954 A1 20060329 EP 2004-758050 20040322 <-  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CA, EE, HJ, PL, SK  
JP 2006208805 ? 20060914 JP 2006-507472 20040322 <-  
MX 2005010086 A 20060210 MX 2005-10086 20050921 <-  
PRIORITY APPL. INFO.: US 2004-45691P P 20050321 <-  
US 2004-804915 A 20040319 <-  
WO 2004-US8809 A 20040322 <-  
IT 1055984-37-6P 1055984-58-1P 1055984-62-7P  
1055985-13-1P  
RL: PAC (Pharmacological activity); PRPH (Propagative); SPW (Synthetic  
preparation); THP (Therapeutic use); BIOL (Biological study); PREP  
(Preparation); USES (Uses)  
(preparation of benzimidazole, benzoxazole and benzothiazole derivs. as  
kinase inhibitors)  
RU 1055984-37-6 CAPLUS  
CN 3-Pyridinacboxamide, 4-[[2-[(3,4-dichlorophenyl)amino]-1H-benzimidazol-6-  
yl]amino]-N-methyl- (CA INDEX NAME)




RN 1055984-62-7 CAPLUS  
CN 1H-Benzimidazole-2,6-diamine, N2-(4-bromophenyl)-N6-(6,7-dimethoxy-4-  
quinolinyl)- (CA INDEX NAME)



RN 1055984-62-7 CAPLUS  
CN 1H-Benzimidazole-2,6-diamine, N2-(4-cyclohexylphenyl)-N6-[2-(methylamino)-  
4-pyridinyl]- (CA INDEX NAME)



PN 1055985-13-1 CAPLUS  
CN 1H-Benzimidazole-2,6-diamine, N2-(3-fluorophenyl)-N6-4-quinolinyl- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)  
REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

15 ANSWER 2 OF 36 CAPLUS COPYRIGHT 2009 ACS ON STN  
ACCESSION NUMBER: 2006:343955 CAPLUS <<LOGIND:20091110>>  
DOCUMENT NUMBER: 144:390936

TITLE: Aryl nitrogen-containing bicyclic compounds and their preparation, pharmaceutical compositions, and protein kinase inhibitory activity and use in prophylaxis and treatment of kinase-mediated diseases

INVENTOR(S): Patel, Vinod F.; Kim, Joseph L.; Geuns-Meyer, Stephanie D.; Chaffee, Stuart C.; Cee, Victor J.; Hodous, Brian L.; Bellon, Steven; Harnange, Jean-Christophe; Olivieri, John R.; Thanan, Maya C.; Dimauro, Erin F.; Buchanan, Philip L.; Mowpan, David C.; Albrecht, Brian K.; Deak, Holly L.; Benis, Jean E.; White, Ryan; Martin, Matthew N.; Hagood, Gregory J.; Tempest, Paul A.; Masse, Craig E.; Buckner, William E.; Herberich, Bradley J.; Graeffe, Russell; Zhang, Dewi; Xu, Shimin; Shan, Melvin; Passa, Robert W.; Falsely, James Richard; Chakrabarti, Partha P.; Cao, Guo-Qiang; Tomlinson, Susan Ann; Petrus, Liping H.; Smith, Adrian Leonard; Paras, Nick A.; Liu, Gang; Democin, Frenel F.; Tasker, Andrew; Reed, Anthony

PATENT ASSIGNEE(S): Aspen Inc., USA  
SOURCE: PCT Int. Appl., 876 pp.  
CODEN: PEXD2

DOCUMENT TYPE: Patent  
LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006039718	A2	20060413	WO 2005-US35873	20051003 <--
WO 2006039718	A3	20060713		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CE, CH, CO, CR, CU, CZ, DE, DK, DM, DO, EC, EG, ES, FI, GB, GD, GE, GF, GR, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LF, LR, LS, LT, LU, LV, LY, MA, MD, MG, MH, MI, MN, MO, MP, MS, MT, MU, NA, NC, NE, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SH, SI, SM, SN, SY, TD, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CE, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GW, GQ, GW, ML, MR, NE, SN, TD, TG, BG, GE, GM, HE, LS, MG, MT, NA, SD, SL, SZ, TO, UG, ZM, ZW, AM, AZ, BY, ES, FZ, MG, RU, T7, TW				
AU 20070054914	A1	20070308	US 2005-240590	20050930 <--
AU 2005292152	A1	20060413	AU 2005-292152	20061003 <--
CA 2582029	A1	20060413	CA 2005-2582029	20061003 <--
EP 1836174	A2	20070926	EP 2005-818381	20061003 <--
R: AT, BE, BG, CE, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GW, GQ, GW, ML, MR, NE, SN, TD, TG, BG, GE, GM, HE, LS, MG, MT, NA, SD, SL, SZ, TO, UG, ZM, ZW, AM, AZ, BY, ES, FZ, MG, RU, T7, TW				
JP 2008051812	T	20080515	JP 2007-534914	20061003 <--
MX 2007003784	A	20070424	MX 2007-3784	20070329 <--
PRIORITY APPL. INFO.:				
			US 2005-240590	A 20050930
			WO 2005-US35873	W 20051003

OTHER SOURCE(S): CASREACT 144:390936; MARPAT 144:390936  
IT 682674-24-0P  
RL: PNC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(drug candidate; preparation of aryl nitrogen-containing bicyclic compds.

and their protein kinase inhibitory activity and use in prophylaxis and treatment of kinase-mediated diseases)

RN 682674-24-0 CAPLUS  
CK Z-Quinazolinamine, N-methyl-6-[2-methyl-5-[(6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl)amino]phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)


15 ANSWER 3 OF 36 CAPLUS COPYRIGHT 2009 ACS ON STN  
ACCESSION NUMBER: 2005:696902 CAPLUS <<LOGIND:20091110>>

DOCUMENT NUMBER: 143:194003  
 TITLE: Preparation of aminobenzazoles and analogs as P2Y1 receptor inhibitors for treating thromboembolic disorders  
 INVENTOR(S): Herpin, Timothy F.; Morton, George C.; Rehfuess, Robert P.; Lawrence, R. Michael; Poss, Michael A.; Roberge, Jacques Y.; Gungor, Timur  
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA  
 SOURCE: PCT Int. Appl., 256 pp.  
 CODEN: FHXDX2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005070920	A1	20050804	WO 2005-781705	20050120 <-
W: AG, AG, AI, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GR, HU, IE, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NI, NL, NO, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SI, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
R: BW, GB, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, GR, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, SR, TR, BF, BJ, CF, CG, CI, CM, GN, GW, GQ, NG, NL, MR, NE, SN, TD, TG				
US 2005070920	A1	20050915	US 2005-38862	20050119 <-
US 7470712	B2	20081230		
EP 1706398	A1	20061004	EP 2005-711663	20050120 <-
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, TS, YU				
JP 2007518809	T	20070712	JP 2006-551237	20050120 <-
NO 2006003191	A	20061016	NO 2006-3191	20060710 <-
US 20080275090	A1	20081106	US 2008-104732	20080417 <-
PRIORITY APPLN. INFO.:				
			US 2004-537869P	P 20040121 <-
			US 2004-638167P	P 20041222 <-
			US 2005-38862	A3 20050119
			WO 2005-781705	W 20050120

OTHER SOURCE(S): CASREACT 143:194003; MARPAT 143:194003  
 IT 861670-93-1P 861670-94-2P,  
 N-[2-[(2-tert-Butylphenyl)oxy]-6-methoxypyridin-3-yl]-4-nitro-1H-benzo[d]imidazol-2-amine 861670-96-4P,  
 N-[2-[(2-tert-Butylphenyl)oxy]-6-methoxypyridin-3-yl]-5-nitro-1H-benzo[d]imidazol-2-amine 861671-18-3P,  
 N-[2-[(2-tert-Butylphenyl)oxy]-6-methoxypyridin-3-yl]-5-[(1H-imidazol-1-yl)-7-methyl-1H-benzo[d]imidazol-2-amine 861671-20-7P,  
 4-Nitro-N-[2-[(3-(trifluoromethyl)phenoxy]pyridin-3-yl]-1H-benzo[d]imidazol-2-amine 861671-22-9P, 5-Nitro-N-[2-[(3-(trifluoromethyl)phenoxy]pyridin-3-yl]-1H-benzo[d]imidazol-2-amine 861671-24-9P, N-[2-[(2-tert-Butylphenyl)oxy]pyridin-3-yl]-5-methyl-3H-benzo[d]imidazo[e-2,4-diamine 861671-96-1P,  
 N-[2-[(2-tert-Butylphenyl)oxy]pyridin-3-yl]-6-(morpholino)-1H-benzo[d]imidazol-2-amine 861671-98-9P,  
 N-[2-[(2-tert-Butylphenyl)oxy]pyridin-3-yl]-N',N'-dimethyl-3H-benzo[d]imidazo[e-2,5-diamine 861674-50-2P  
 RL: PNC (Pharmacological activity); SPN (Synthetic preparation); THD (Therapeutic use); BTOL (Biological study); PREP (Preparation); DESSE


(Uses)  
 (drug candidate; preparation of aminobenzazoles and analogs as P2Y1 receptor inhibitors for treating thromboembolic disorders)  
 RN 861670-93-1 CAPLUS  
 CN 1H-Benzimidazol-2-amine, N-[2-[(1,1-dimethylethyl)phenoxy]-3-pyridinyl]-5-[(1H-imidazol-1-yl)-7-methyl- (CA INDEX NAME)



RN 861670-94-2 CAPLUS  
 CN 1H-Benzimidazol-2-amine, N-[2-[(2-(1,1-dimethylethyl)phenoxy)-6-methoxy-3-pyridinyl]-7-nitro- (CA INDEX NAME)




RN 861670-96-4 CAPLUS  
 CN 1H-Benzimidazol-2-amine, N-[2-[(1,1-dimethylethyl)phenoxy]-6-methoxy-3-pyridinyl]-6-nitro- (CA INDEX NAME)




RN 861671-18-3 CAPLUS

CN 1H-Benzimidazol-2-amine, N-[2-(2-(1,1-dimethylethyl)phenoxy]-6-methoxy-3-pyridinyl]-5-(1H-imidazol-1-yl)-7-methyl- (CA INDEX NAME)




RN 861671-20-7 CAPLUS

CN 1H-Benzimidazol-2-amine, 7-nitro-N-[2-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]- (CA INDEX NAME)




RN 861671-22-9 CAPLUS

CN 1H-Benzimidazol-2-amine, 6-nitro-N-[2-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]- (CA INDEX NAME)




RN 861671-92-3 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N2-[2-(2-(1,1-dimethylethyl)phenoxy)-3-pyridinyl]-6-methyl- (CA INDEX NAME)




RN 861671-96-7 CAPLUS

CN 1H-Benzimidazol-2-amine, N-[2-(2-(1,1-dimethylethyl)phenoxy)-3-pyridinyl]-6-(4-morpholinyl)- (CA INDEX NAME)



RN 861671-98-9 CAPLUS


CN 1H-Benzimidazole-2,6-diamine, N2-[2-(2-(1,1-dimethylethyl)phenoxy)-3-pyridinyl]-N6,N6-dimethyl- (CA INDEX NAME)



RN 861674-50-2 CAPLUS

CN 1H-Benzimidazol-2-amine, N-[2-(2-(1,1-dimethylethyl)phenoxy)-3-pyridinyl]-

6-methyl-7-nitro- (CA INDEX NAME)




IT 1026562-20-8P

RL: SYN (Synthetic preparation); PREP (Preparation)

(preparation of aminobenzazoles and analogs as P2Y1 receptor inhibitors for treating thromboembolic disorders)

RM 1026562-20-8 CAPLUS

CN 1H-Benzimidazol-2-amine, N-[2-[2-(1,1-dimethylethyl)phenoxy]-3-pyridinyl]-7-nitro- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

15 ANSWER 4 OF 36 CAPLUS COPYRIGHT 2009 ACS ON SYN

ACCESSION NUMBER: 2005:429393 CAPLUS <<LOGIND>:20091110>>

DOCUMENT NUMBER: 142:482043

TITLE: Preparation of nitrogen-containing fused heterocyclic compounds like benzimidazoles and benzothiazoles as CRF receptor antagonists

INVENTOR(S): Gyorkos, Albert Charles; Corrette, Christopher Peter; Cho, Suk Young; Turner, Timothy Mark; Pratt, Scott Alan; Aso, Kazuyoshi; Kori, Masakuni; Gyoten, Michiyo Takeda Pharmaceutical Company Limited, Japan

PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Japan

SOURCE: PCT Int. Appl., 273 pp.

COHEN: PEIX02

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005044793	A2	20050519	WO 2004-US35648	20041027 <--
WO 2005044793	A3	20060330		
W: AG, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CE, CH, CI, CR, CU, CY, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GF, GM, GN, GR, HU, IE, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MU, MV, NA, NE, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, ST, SV, TH, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GE, GM, KE, LS, MW, NE, NA, SD, SL, SS, TG, TZ, ZM, ZW, AG, BG, BR, CH, CN, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BE, CE, CG, CI, CM, CN, CO, CZ, DE, EG, GM, KE, MG, NE, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, ST, SV, TH, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
CA 2543707	A1	20050519	CA 2004-2543707	20041027 <--
EP 1477191	A2	20060712	EP 2004-810065	20041027 <--
IE: AT, BG, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PD, TR, SI, LT, LV, PT, RO, MK, CY, AL, TR, BG, CZ, EG, HU, FI, SK, HR JP 2007510446 T 20070426 JP 2006-538217 20060428 US 20070135452 A1 20070614 US 2006-577334 20060428				
PRIORITY APPLN. INFO.:				P 20031031 <--
				US 2004-560518P P 20040408 <--
				WO 2004-US35648 W 20041027


OTHER SOURCE(S): CASREACT 142:482043; NARPAT 142:482043

IT 851886-96-9P, N'-Benzyl-N-mesityl-1-methyl-N'-propyl-1H-benzimidazole-2,7-diamine 851888-22-7P, 4-[[2-(4-Bromo-2-methoxy-6-methylphenylamino)-1-methyl-1H-benzimidazol-7-yl](isopropylamino)butanoic acid 851888-23-8P, Methyl 4-[[2-[[4-bromo-2-methoxy-6-methylphenylamino)-1-methyl-1H-benzimidazol-7-yl](isopropylamino)butanoate 851888-51-2P, Ethyl N-[2-[[4-chloro-2-methoxy-6-methylphenylamino)-1-methyl-1H-benzimidazol-7-yl]-N-(4-methoxyphenyl)glycinate 851888-76-1P, 5-Chloro-2-[[7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]phenol 851889-02-6P, N-[2-(3-Bromopropoxy)-4-chlorophenyl]-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851889-03-7P, 4-[5-Chloro-2-[[7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]phenoxy]butanenitrile 851889-08-2P, 4-[5-Chloro-2-[[7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]phenoxy]butyric acid  
 RU: PNC (Pharmacological activity); RCT (Reactant); SYN (Synthetic preparation); THU (Therapeutic use); BIO (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (drug candidate; preparation of nitrogen-containing fused heterocyclic compounds.


like benzimidazoles and benzothiazoles as CRF receptor antagonists with therapeutic potential]

RM 851886-96-9 CAPLUS


CN 1H-Benzimidazole-2,7-diamine, 1-methyl-N'-(phenylmethyl)-N'-propyl-N'-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851888-22-7 CASLUS  
CN Butanoic acid, 4-[[2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl]] (1-methylethyl)amino]- (CA INDEX NAME)




RN 851888-23-8 CASLUS  
CN Butanoic acid, 4-[[2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl]] (1-methylethyl)amino]-, methyl ester (CA INDEX NAME)




RN 851888-51-2 CASLUS  
CN Glycine, N-[2-[(4-chloro-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl]-N-(4-methoxyphenyl)-, ethyl ester (CA INDEX NAME)




RN 851889-76-1 CASLUS  
CN Phenol, 5-chloro-2-[[7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]- (CA INDEX NAME)



RN 851889-02-6 CASLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(2-(3-bromopropoxy)-4-chlorophenyl)-1-methyl-N7-dipropyl- (CA INDEX NAME)




RN 851889-03-7 CASLUS  
CN Butanenitrile, 4-[5-chloro-2-[[7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]phenoxy]- (CA INDEX NAME)





RN 851889-08-2 CAPLUS  
CN Butanoic acid, 4-[5-chloro-2-[[7-(diisopropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]phenoxy]- (CA INDEX NAME)



IT 851886-84-5B, N-Mesityl-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851886-87-6P,  
N-Mesityl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine  
851886-89-9P, 1-Isopropyl-N-mesityl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851886-89-0P,  
N-Mesityl-1-phenyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine  
851886-90-3P, 1-Ethyl-N-mesityl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851886-91-4P,  
N'-Cyclopropylmethyl-N-mesityl-1-methyl-N'-propyl-1H-benzimidazole-2,7-diamine 851886-93-2P, 1-Methyl-N-phenyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-03-1P,  
Methyl 4-[[7-(diisopropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]-3-methylbenzoate trifluoroacetate 851887-05-3P,  
N-(2,6-Dimethoxy-pyridin-3-yl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-07-5P,  
N-(4-tert-Butyl-2,6-dimethylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-09-7P,  
N-(2,4-Dimethylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-11-1P,  
N-(4-Bromo-2-ethylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-13-3P,  
N-(4-Dimethylamino)-2-methylphenyl-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-15-5P,  
1-Methyl-N-(4-methyl-5-nitropyridin-2-yl)-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-17-7P,  
N-(2,4-Dichlorophenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-19-9P,  
N-(2-Chloro-4,6-dimethylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-21-3P,  
N-(2-Bromo-4-isopropylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-23-5P,  
1-Methyl-N',N'-dipropyl-N-(2,4,6-trichlorophenyl)-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-27-3P,  
N-(4,5-Dimethoxy-2-methylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-29-1P,  
N-(2,6-Dimethylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-31-5P,  
2,4-Dichloro-4-[[7-(diisopropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]-3-methylbenzoate trifluoroacetate 851887-33-7P,  
N-(3,5-Dichloropyridin-4-yl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-35-9P,  
N-(3-Bromo-5-methylpyridin-2-yl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-37-1P,  
N-(3,5-Dimethoxyphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-

diamine trifluoroacetate 851887-39-3P,  
1-Methyl-N-(2-methyl-4-(trifluoromethoxy)phenyl)-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-41-7P,  
N-(2,4-Dimethoxyphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine trifluoroacetate 851887-42-8P,  
N',N'-Dibutyl-1H-mesityl-1-methyl-1H-benzimidazole-2,7-diamine 851887-43-9P, N',N'-Bis(cyclopropylmethyl)-N-mesityl-1-methyl-1H-benzimidazole-2,7-diamine 851887-44-0P,  
N-Mesityl-1-methyl-7-(piperidin-1-yl)-1H-benzimidazol-2-amine 851887-45-1P, N'-Butyl-N-mesityl-1-methyl-N'-propyl-1H-benzimidazole-2,7-diamine 851887-46-2P,  
N-Mesityl-1-methyl-N'-(2-methoxyethyl)-N'-propyl-1H-benzimidazole-2,7-diamine 851887-47-3P, N'-Isobutyl-N-mesityl-1-methyl-N'-propyl-1H-benzimidazole-2,7-diamine 851887-55-3P,  
5-Fluoro-N-mesityl-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851887-57-5P, N',N'-Dibutyl-5-Fluoro-N-mesityl-1-methyl-1H-benzimidazole-2,7-diamine hydrochloride 851887-58-6P,  
N',N'-Bis(cyclopropylmethyl)-5-Fluoro-N-mesityl-1-methyl-1H-benzimidazole-2,7-diamine hydrochloride 851887-59-7P,  
N'-Butyl-N-mesityl-N'-(4-methoxyphenyl)-1-methyl-1H-benzimidazole-2,7-diamine 851887-63-3P, N-Mesityl-N'-propyl-1-methyl-N'-propyl-1H-benzimidazole-2,7-diamine 851887-64-4P,  
N'-Isopropyl-N-mesityl-1-methyl-N'-propyl-1H-benzimidazole-2,7-diamine 851887-65-5P, N-Mesityl-1-methyl-N'-(4-propylbutyl)-1H-benzimidazole-2,7-diamine 851887-66-6P,  
N'-Benzyl-N'-(cyclopropylmethyl)-N-mesityl-1-methyl-1H-benzimidazole-2,7-diamine 851887-67-7P, N'-(4-chlorobenzyl)-N'-(cyclopropylmethyl)-N-mesityl-1-methyl-1H-benzimidazole-2,7-diamine 851887-68-8P, N'-(Cyclopropylmethyl)-N-mesityl-N'-(4-methoxybenzyl)-1-methyl-1H-benzimidazole-2,7-diamine 851887-69-9P, N'-(Cyclopropylmethyl)-N-mesityl-1-methyl-N'-(pyridin-3-ylmethyl)-1H-benzimidazole-2,7-diamine 851887-70-2P,  
(N'-Cyclopropylmethyl)-N-[2-(mesitylamino)-1-methyl-1H-benzimidazol-7-yl]acetamide 851887-71-3P,  
N'-(4-tert-Butylbenzyl)-N'-(cyclopropylmethyl)-N-mesityl-1-methyl-1H-benzimidazole-2,7-diamine 851887-72-4P,  
N'-(Cyclopropylmethyl)-N-mesityl-1-methyl-N'-(4-methylbenzyl)-1H-benzimidazole-2,7-diamine 851887-73-5P,  
N'-(Cyclopropylmethyl)-N-mesityl-1-methyl-N'-(pyridin-4-ylmethyl)-1H-benzimidazole-2,7-diamine 851887-74-6P,  
N'-(Cyclopropylmethyl)-N-mesityl-1-methyl-N'-(4-(trifluoromethyl)benzyl)-1H-benzimidazole-2,7-diamine 851887-75-7P,  
N'-(Cyclopropylmethyl)-N'-(4-fluorobenzyl)-N-mesityl-1-methyl-1H-benzimidazole-2,7-diamine 851887-76-8P,  
4-[(Cyclopropylmethyl)-2-(mesitylamino)-1-methyl-1H-benzimidazol-7-yl]amino(methyl)benzonitrile 851887-77-9P,  
N'-(Cyclopropylmethyl)-N-mesityl-1-methyl-N'-(pyridin-2-ylmethyl)-1H-benzimidazole-2,7-diamine 851887-78-0P,  
N'-(2-Benzylloxyethyl)-N'-(cyclopropylmethyl)-N-mesityl-1-methyl-1H-benzimidazole-2,7-diamine 851887-79-1P,  
2-[(Cyclopropylmethyl)-2-(mesitylamino)-1-methyl-1H-benzimidazol-7-yl]amino(ethyl)benzonitrile 851887-80-4P,  
N-(4-Bromo-2,6-dimethylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851887-81-5P,  
N-(4-Methoxy-2-methylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851887-82-6P, N-(2,6-Dimethoxy-4-methylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851887-83-7P,  
N'-(4-Bromo-2-methoxy-6-methylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851887-84-8P,  
N-(2,6-Dichloropyridin-3-yl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851887-85-9P, 4-[[7-(Diisopropylamino)-1-methyl-1H-

benzimidazol-2-yl]amino]-3-ethylbenzonitrile 851887-85-0F,  
N-(2,4-Dimethoxy-6-methylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine hydrochloride 851887-87-1F,  
N-(2,4-Dichloro-6-methylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine hydrochloride 851887-88-2F,  
N-[2-Chloro-6-(trifluoromethyl)pyridin-3-yl]-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine hydrochloride 851887-89-3F,  
N-[2-Chloro-4-(trifluoromethyl)phenyl]-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine hydrochloride 851887-90-6F,  
N-(2-Bromo-4-methoxy-6-methylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine hydrochloride 851887-91-7F,  
N-(4-Chloro-2-methoxy-5-methylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine hydrochloride 851887-92-8F,  
N-(4-Bromo-2-methylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine hydrochloride 851887-93-9F,  
N'-(Cyclopropylmethyl)-N''-(2,4-dimethylbenzyl)-N-mesityl-1-methyl-1H-benzimidazole-2,7-diamine hydrochloride 851887-94-0F,  
N-(4-Bromo-2-ethylphenyl)-N',N'-dibutyl-1-methyl-1H-benzimidazole-2,7-diamine hydrochloride 851887-95-1F,  
N-(4-Chloro-2-isopropyl-6-methylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine hydrochloride 851887-96-2F,  
N',N'-Dibutyl-N''-(2,4-dimethoxy-6-methylphenyl)-1-methyl-1H-benzimidazole-2,7-diamine hydrochloride 851887-97-3F,  
N-(2-Bromo-4-methoxy-6-methylphenyl)-N',N'-dibutyl-1-methyl-1H-benzimidazole-2,7-diamine hydrochloride 851887-99-5F,  
N-Mesityl-1-(2-methoxyethyl)-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851888-00-1P, N-Mesityl-N',N'-dipropyl-1-(2,2,2-trifluoroethyl)-1H-benzimidazole-2,7-diamine 851888-01-2F,  
2-[7-(Dipropylamino)-2-(mesitylamino)-1H-benzimidazol-1-yl]ethanol 851888-02-3F, N',N'-Bis(cyclopropylmethyl)-1-methyl-N''-(2,4,6-trimethylpyridin-3-yl)-1H-benzimidazole-2,7-diamine 851888-03-4F,  
1-Acetyl-N-mesityl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851888-04-5F, N',N'-Dibutyl-N-mesityl-1-(2,2,2-trifluoroethyl)-1H-benzimidazole-2,7-diamine 851888-05-6F,  
N',N'-Bis(cyclopropylmethyl)-N-mesityl-1-(2,2,2-trifluoroethyl)-1H-benzimidazole-2,7-diamine 851888-06-7F,  
4-Bromo-N-mesityl-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851888-12-5F, N-(2,4,6-Trimethylpyridin-3-yl)-1-methyl-N',N'-di(2-methoxyethyl)-1H-benzimidazole-2,7-diamine hydrochloride 851888-18-1P, N-(4-Bromo-2-methoxy-6-methylphenyl)-N',N'-bis(2-methoxyethyl)-1-methyl-1H-benzimidazole-2,7-diamine 851888-20-5F,  
N-(4-Bromo-2-methoxy-6-methylphenyl)-N''-(2-methoxyethyl)-N-methyl-1-methyl-1H-benzimidazole-2,7-diamine 851888-21-6F,  
N-(4-Bromo-2-methoxy-6-methylphenyl)-N-isopropyl-N''-(2-methoxyethyl)-1-methyl-1H-benzimidazole-2,7-diamine 851888-24-9F,  
4-[[2-(4-Bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl](isopropyl)amino)-N-methylbutanamide 851888-25-0F,  
4-[[2-(4-Bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl](isopropyl)amino)-N,N'-dimethylbutanamide 851888-26-1F,  
N-(4-Bromo-2-methoxy-6-methylphenyl)-N-isopropyl-1-methyl-N''-(4-oxo-4-(pyrrolidin-1-yl)butyl)-1H-benzimidazole-2,7-diamine 851888-27-2F, 4-[[2-(4-Bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl](isopropyl)amino)-N,N'-diethylbutanamide 851888-28-3F,  
N-(4-Bromo-2-methoxy-6-methylphenyl)-N-isopropyl-1-methyl-N''-(4-morpholin-4-yl)-4-oxobutyl-1H-benzimidazole-2,7-diamine 851888-29-4F, N-(4-Bromo-2-methoxy-6-methylphenyl)-N-isopropyl-1-methyl-N''-(4-oxo-4-(piperidin-1-yl)butyl)-1H-benzimidazole-2,7-diamine 851888-30-7F, N-(4-Bromo-2-methoxy-6-methylphenyl)-N-isopropyl-1-methyl-N''-(4-oxo-4-(4-thiomorpholinyl)butyl)-1H-benzimidazole-2,7-diamine 851888-31-8F, N-(4-Bromo-2-methoxy-6-methylphenyl)-N-isopropyl-1-methyl-N''-(4-(4-methylpiperazin-1-yl)-4-oxobutyl)-1H-benzimidazole-2,7-

diamine 851888-32-9F, N'-[2-(4-Bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl]-N''-isopropylglycinamide 851888-33-0F, N''-(2-Aminoethyl)-N-(4-bromo-2-methoxy-6-methylphenyl)-N'-isopropyl-1-methyl-1H-benzimidazole-2,7-diamine Hydrochloride 851888-35-2F,  
N-(4-Chloro-2-methoxy-6-methylphenyl)-N''-[2-(dimethylamino)ethyl]-N'-isopropyl-1-methyl-1H-benzimidazole-2,7-diamine Hydrochloride 851888-37-4F, N-(4-Chloro-2-methoxy-6-methylphenyl)-N''-(4-chlorophenyl)-N'-isopropyl-1-methyl-1H-benzimidazole-2,7-diamine Hydrochloride 851888-43-2F,  
N-(4-Chloro-2-methoxy-6-methylphenyl)-N''-(4-chlorophenyl)-1-methyl-N'-neopropyl-1H-benzimidazole-2,7-diamine hydrochloride 851888-44-3F, N-(4-Chloro-2-methoxy-6-methylphenyl)-N''-(4-chlorophenyl)-N''-(2-methoxyethyl)-1-methyl-1H-benzimidazole-2,7-diamine hydrochloride 851888-45-4F, Ethyl N-[2-(4-chloro-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl]-N-(4-chlorophenyl)glycinamide hydrochloride 851888-46-5F, N'-[2-(4-Chloro-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl]-N''-(4-chlorophenyl)-N,N'-dimethylglycinamide hydrochloride 851888-47-6F, N-(4-Chloro-2-methoxy-6-methylphenyl)-N''-(4-chlorophenyl)-1-methyl-N'-[tetrahydrofuran-3-yl)methyl]-1H-benzimidazole-2,7-diamine 851888-49-8F, N-(4-Chloro-2-methoxy-6-methylphenyl)-N'-isopropyl-N''-(4-methoxyphenyl)-1-methyl-1H-benzimidazole-2,7-diamine 851888-50-1P, N-(4-Chloro-2-methoxy-6-methylphenyl)-N''-(2-methoxyethyl)-N''-(4-methoxyphenyl)-1-methyl-1H-benzimidazole-2,7-diamine 851888-52-3P, N-(4-Chloro-2-methoxy-6-methylphenyl)-N''-(4-methoxyphenyl)-1-methyl-N''-(tetrahydro-2H-pyran-4-yl)methyl)-1H-benzimidazole-2,7-diamine 851888-53-4P,  
N-(4-Chloro-2-methoxy-6-methylphenyl)-N'-isopropyl-1-methyl-N''-(5-methylpyridin-2-yl)-1H-benzimidazole-2,7-diamine 851888-54-5F, N-(4-Chloro-2-methoxy-6-methylphenyl)-N''-(2-methoxyethyl)-1-methyl-N''-(5-methylpyridin-2-yl)-1H-benzimidazole-2,7-diamine 851888-55-6F, N'-[2-(4-Chloro-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl]-N,N'-diethyl-N''-(4-methoxyphenyl)glycinamide Hydrochloride 851888-56-7P, N-[2-(4-Chloro-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl]-N-(4-chlorophenyl)acetamide Hydrochloride 851888-58-9F, N-[2-(4-Chloro-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl]-N-(4-methoxyphenyl)acetamide 851888-59-0P, N-(4-Bromo-2-methoxy-6-methylphenyl)-N'-isopropyl-1-methyl-N''-(4-methylsulfonylphenyl)-1H-benzimidazole-2,7-diamine 851888-61-4F, N-(4-Bromo-2-methoxy-6-methylphenyl)-N-isopropyl-1-methyl-N''-[3-(methylsulfonyl)phenyl]-1H-benzimidazole-2,7-diamine 851888-62-5F, N-(4-Bromo-2-methoxy-6-methylphenyl)-N-ethyl-N'-isopropyl-1-methyl-1H-benzimidazole-2,7-diamine hydrochloride 851888-63-6F, N-(4-Bromo-2,6-dimethylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851888-64-7F, N-(4-Bromo-2-methoxy-6-methylphenyl)-N',N'-dibutyl-1-methyl-1H-benzimidazole-2,7-diamine 851888-65-0P, N-(4-Bromo-2,6-dimethylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851888-66-5F, Methyl 4-[(cyclopropylmethyl)[2-(mesitylamino)-1-methyl-1H-benzimidazol-7-yl]amino]butanoate 851888-67-0P, N-(4-Bromo-2-methoxy-6-methylphenyl)-N',N'-diethyl-1-methyl-1H-benzimidazole-2,7-diamine 851888-68-1P, N-(4-Chloro-2-methoxy-6-methylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851888-69-2F, N-(3,4-Dichloro-2-methoxy-6-methylphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851888-70-5P,


N-(4-Bromo-2-methoxy-6-methylphenyl)-N'-isopropyl-N'-methyl-1-methyl-1H-benzimidazole-2,7-diamine 851888-71-6P,  
N'-Ethyl-N'-isopropyl-1-methyl-N-(2,4,6-trimethoxyphenyl)-1H-benzimidazole-2,7-diamine 851888-72-7P,  
N-(4-Chloro-2-methoxy-6-methylphenyl)-N'-ethyl-N'-isopropyl-1-methyl-1H-benzimidazole-2,7-diamine 851888-73-8P,  
N-(4-Chloro-2-methoxy-6-methylphenyl)-N',N'-diethyl-1-methyl-1H-benzimidazole-2,7-diamine 851888-74-9P,  
N-(4-Chloro-2,6-diethylphenyl)-N',N'-diethyl-1-methyl-1H-benzimidazole-2,7-diamine 851888-75-0P, N-(4-Chloro-2,6-diethylphenyl)-N'-methyl-N'-isopropyl-1-methyl-1H-benzimidazole-2,7-diamine 851888-77-2P,  
[5-Chloro-2-[[7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]phenyl]methanol 851888-78-3P,  
N-(4-Chloro-2-methoxyphenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851888-79-4P, N-(2-Bromo-4-chlorophenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851888-81-8P,  
5-Chloro-2-[[7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]benzonitrile 851888-82-9P,  
N-(4-Chloro-2-(methoxymethyl)phenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851888-83-0P,  
N',N'-bis[2-(benzoyloxyethyl)-1-methyl-N-(2,4,6-trimethylpyridin-3-yl)-1H-benzimidazole-2,7-diamine 851888-84-1P,  
N-(4-Chloro-2-ethoxyphenyl)-3-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851888-85-2P, 1-Methyl-N-(pentamethylphenyl)-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851888-86-3P,  
N-(4-Bromo-2-methoxy-6-methylphenyl)-7-(2-ethyl-1-piperidinyl)-1-methyl-1H-benzimidazole-2-amine 851888-89-6P,  
N-(4-Bromo-2-methoxy-6-methylphenyl)-1-methyl-7-(2-methylpiperidin-1-yl)-1H-benzimidazole-2-amine 851888-90-3P,  
N-(4-Bromo-2-methoxy-6-methylphenyl)-7-(2-ethyl-1-pyrrolidinyl)-1-methyl-1H-benzimidazole-2-amine 851888-91-0P,  
N-(4-Bromo-2-methoxy-6-methylphenyl)-1-methyl-7-(2-methyl-1H-pyrrolidin-1-yl)-1H-benzimidazole-2-amine 851888-92-1P,  
N-(4-Bromo-2-methoxy-6-methylphenyl)-7-(3-ethyl-4-morpholinyl)-1-methyl-1H-benzimidazole-2-amine 851888-93-2P,  
N-(4-Bromo-2-methoxy-6-methylphenyl)-1-methyl-7-(2-propyl-1-piperidinyl)-1H-benzimidazole-2-amine 851888-94-3P,  
N-(4-Bromo-2-methoxy-6-methylphenyl)-1-methyl-7-(2-methoxymethyl-1-piperidinyl)-1H-benzimidazole-2-amine 851888-95-4P,  
N'-[7-(2-Ethyl-1-piperidinyl)-1-methyl-1H-benzimidazol-2-yl]-N,N'-dimethyl-4-methyl-2,5-pyridinediamine 851888-96-5P, Methyl 1-[2-(4-bromo-2-methoxy-6-methylphenylamino)-1-methyl-1H-benzimidazol-7-yl]piperidine-2-carboxylate 851888-04-8P,  
N-(2-(2-Bromoethoxy)-4-chlorophenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851889-05-9P,  
[5-Chloro-2-[[7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]phenoxy]acetoneitrile 851889-06-0P,  
N-(2-(4-Bromobutoxy)-4-chlorophenyl)-1-methyl-N',N'-dipropyl-1H-benzimidazole-2,7-diamine 851889-07-1P,  
5-[5-Chloro-2-[[7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]phenoxy]pentanenitrile 851889-09-3P,  
4-[5-Chloro-2-[[7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]phenoxy]-6-methylbutanamide Hydrochloride 851889-10-6P,  
4-[5-Chloro-2-[[7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]phenoxy]-N,N'-dibutylbutanamide 851889-19-5P,  
N-(4-Bromo-2-methoxy-6-methylphenyl)-N'-propyl-1-methyl-N'-[2-(methanesulfonyl)phenyl]-1H-benzimidazole-2,7-diamine 851889-22-0P, 4-[[2-[(4-Bromo-2-methoxy-6-methylphenylamino)-1-methyl-1H-benzimidazol-7-yl]isopropyl]amino]benzonitrile 851889-28-6P, 4-[[2-[(4-Bromo-2-methoxy-6-methylphenylamino)-1-methyl-1H-benzimidazol-7-yl]isopropyl]amino]-2-methoxybenzonitrile

RI: FMC (Pharmacological activity); SPN (Synthetic preparation); TBT (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(drug candidate; preparation of nitrogen-containing fused heterocyclic compds.

Like benzimidazoles and benzothiazoles as CRF receptor antagonists with therapeutic potential)


RM 851886-84-5 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, 1-methyl-N7,N7-dipropyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RM 851886-87-8 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N7,N7-dipropyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RM 851886-88-9 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, 1-(1-methylethyl)-N7,N7-dipropyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RM 851886-89-0 CAPLUS


CN 1H-Benzimidazole-2,7-diamine, 1-phenyl-N7,N7-dipropyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)



RN 851886-90-3 CAFLUS  
CN 1H-Benzimidazole-2,7-diamine, 1-ethyl-N7,N7-dipropyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)



RN 851886-91-4 CAFLUS  
CN 1H-Benzimidazole-2,7-diamine, N7-(cyclopropylmethyl)-1-methyl-N7-propyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)



RN 851886-99-2 CAFLUS  
CN 1H-Benzimidazole-2,7-diamine, 1-methyl-N2-phenyl-N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CN 1

CN 851886-98-1  
CN C20 H26 N4



CN 2


CN 76-05-1  
CN C2 H F3 O2



RN 851887-03-1 CAFLUS  
CN Benzoic acid, 4-[[7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]-3-methyl-, methyl ester, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CN 1

CN 851887-02-0  
CN C23 H30 N4 O2



CN 2


CN 76-05-1  
CN C2 H F3 O2



RN 851887-05-3 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(2,6-dimethoxy-3-pyridinyl)-1-methyl-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 851887-04-2  
CMF C21 E29 N5 O2



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 851887-07-5 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-[4-(1,1-dimethylethyl)-2,6-dimethylphenyl]-1-methyl-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 851887-06-4  
CMF C26 E38 N4



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 851887-09-7 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(2,4-dimethylphenyl)-1-methyl-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 851887-08-6  
CMF C22 E30 N4



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 851887-11-1 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-ethylphenyl)-1-methyl-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 851887-10-0  
CMF C22 E29 Br N4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 851887-13-3 CAPLUS

CM 1H-Benzimidazole-2,7-diamine, N2-(4-(diethylamino)-2-methylphenyl)-1-methyl-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 851887-12-2

CMF C25 H37 N5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 851887-15-5 CAPLUS

CM 1H-Benzimidazole-2,7-diamine, 1-methyl-N2-(4-methyl-5-nitro-2-pyridinyl)-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 851887-14-4

CMF C20 H26 N6 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 851887-17-7 CAPLUS

CM 1H-Benzimidazole-2,7-diamine, N2-(2,4-dichlorophenyl)-1-methyl-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 851887-16-6

CMF C20 H24 Cl2 N4




CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 851887-19-9 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamine, N2-(2-chloro-4,6-dimethylphenyl)-1-methyl-  
 N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)  
 CM 1  
 CRN 851887-18-8  
 CMF C22 H23 Cl N4



CM 2  
 CRN 76-05-1  
 CMF C2 H F3 O2




RN 851887-21-3 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamine, N2-[2-bromo-4-(1-methylethyl)phenyl]-1-  
 methyl-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)  
 CM 1  
 CRN 851887-20-2  
 CMF C23 H31 Br N4



CM 2  
 CRN 76-05-1  
 CMF C2 H F3 O2



RN 851887-23-5 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamine, 1-methyl-N7,N7-dipropyl-N2-(2,4,6-  
 trichlorophenyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)  
 CM 1  
 CRN 851887-22-4  
 CMF C20 H23 Cl3 N4




CM 2  
 CRN 76-05-1  
 CMF C2 H F3 O2



RN 851887-27-9 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamine, N2-(4,5-dimethoxy-2-methylphenyl)-1-methyl-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CFM 851887-26-8  
 CMF C23 H32 N4 O2



CM 2


CFM 76-05-1  
 CMF C2 H F3 O2



RN 851887-29-1 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamine, N2-(2,6-dimethylphenyl)-1-methyl-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CFM 851887-28-0  
 CMF C22 H30 N4



CM 2


CFM 76-05-1  
 CMF C2 H F3 O2



RN 851887-31-5 CAPLUS  
 CN Phenol, 2,4-dichloro-6-[[7-(dipropylamino)-1-methyl-1H-benzimidazol-2-ylamino]-3-methyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CFM 851887-30-4  
 CMF C21 H26 Cl2 N4 O



CM 2

CFM 76-05-1  
 CMF C2 H F3 O2




RN 851887-33-7 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamine, N2-(3,5-dichloro-4-pyridinyl)-1-methyl-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CFM 851887-32-5  
 CMF C19 H23 Cl2 N5





CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 851887-35-9 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(3-bromo-5-methyl-2-pyridinyl)-1-methyl-N7, N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 851887-34-8  
CMF C20 H26 Br N5



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 851887-37-1 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(3,5-dimethoxyphenyl)-1-methyl-N7, N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 851887-36-0  
CMF C22 H30 N4 O2



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 851887-39-3 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, 1-methyl-N2-(2-methyl-4-(trifluoromethoxy)phenyl)-N7, N7-dipropyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 851887-38-2  
CMF C22 H27 F3 N4 O



CM 2


CRW 76-05-1  
CMF C2 H F3 O2



RN 851887-41-7 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(2,4-dimethoxyphenyl)-1-methyl-N7,N7-dipropyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRW 851887-40-6  
CMF C22 H30 N4 O2




CM 2


CRW 76-05-1  
CMF C2 H F3 O2




RN 851887-42-8 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N7,N7-dibutyl-1-methyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-43-9 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N7,N7-bis(cyclopropylmethyl)-1-methyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-44-0 CAPLUS  
CN 1H-Benzimidazol-2-amine, 1-methyl-7-(1-piperidinyl)-N-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-45-1 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N7-butyl-1-methyl-N7-propyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-46-2 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N7-(2-methoxyethyl)-1-methyl-N7-propyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-47-3 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, 1-methyl-N7-(2-methylpropyl)-N7-propyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)



RN 851887-55-3 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, 5-fluoro-1-methyl-N7,N7-dipropyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-57-5 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N7,N7-dibutyl-5-fluoro-1-methyl-N2-(2,4,6-trimethylphenyl)-, hydrochloride (1:1) (CA INDEX NAME)




● x HCl

RN 851887-58-6 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N7,N7-bis(cyclopropylmethyl)-5-fluoro-1-methyl-N2-(2,4,6-trimethylphenyl)-, hydrochloride (1:1) (CA INDEX NAME)




● x HCl


RN 851887-59-7 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N7-butyl-N7-(4-methoxyphenyl)-1-methyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-63-3 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N7,1-dimethyl-N7-propyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-64-4 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, 1-methyl-N7-(1-methylethyl)-N7-propyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-65-5 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, 1-methyl-N7-(1-propylbutyl)-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-66-6 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N7-(cyclopropylmethyl)-1-methyl-N7-(phenylmethyl)-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)



RN 851887-67-7 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N7-[(4-chlorophenyl)methyl]-N7-(cyclopropylmethyl)-1-methyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-68-8 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N7-(cyclopropylmethyl)-N7-[(4-methoxyphenyl)methyl]-1-methyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-69-9 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N7-(cyclopropylmethyl)-1-methyl-N7-[(3-pyridinylmethyl)-N2-(2,4,6-trimethylphenyl)]- (CA INDEX NAME)




RN 851887-70-2 CAPLUS

CN Acetamide, N-(cyclopropylmethyl)-N-[(1-methyl-2-[(2,4,6-trimethylphenyl)amino]-1H-benzimidazol-7-yl)]- (CA INDEX NAME)




RN 851887-71-3 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N7-(cyclopropylmethyl)-N7-[(4-(1,1-dimethylethyl)phenyl)methyl]-1-methyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-72-4 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N7-(cyclopropylmethyl)-1-methyl-N7-[(4-methylphenyl)methyl]-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-73-5 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N7-(cyclopropylmethyl)-1-methyl-N7-(4-pyridinylmethyl)-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-74-6 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N7-(cyclopropylmethyl)-1-methyl-N7-[[4-(trifluoromethyl)phenyl]methyl]-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-75-7 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N7-(cyclopropylmethyl)-N7-[[4-fluorophenyl]methyl]-1-methyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-76-8 CAPLUS

CN Benzonitrile, 4-[[[(cyclopropylmethyl)[1-methyl-2-[(2,4,6-trimethylphenyl)amino]-1H-benzimidazol-7-yl]amino]methyl]- (CA INDEX NAME)




RN 851887-77-9 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N7-(cyclopropylmethyl)-1-methyl-N7-[2-pyridinylmethyl]-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-78-0 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N7-(cyclopropylmethyl)-1-methyl-N7-[2-(phenylmethoxy)ethyl]-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851887-79-1 CAPLUS


CN Ethanol, 2-[[[(cyclopropylmethyl)[1-methyl-2-[(2,4,6-trimethylphenyl)amino]-1H-benzimidazol-7-yl]amino]- (CA INDEX NAME)




RN 851887-80-4 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2,6-dimethylphenyl)-1-methyl-N7,N7-dipropyl- (CA INDEX NAME)




RN 851887-81-5 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4-methoxy-2-methylphenyl)-1-methyl-N7,N7-dipropyl- (CA INDEX NAME)




RN 851887-82-6 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(2,6-dimethoxy-4-methylphenyl)-1-methyl-N7,N7-dipropyl- (CA INDEX NAME)




RN 851887-83-7 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methoxy-6-methylphenyl)-1-methyl-N7,N7-dipropyl- (CA INDEX NAME)




RN 851887-84-8 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(2,6-dichloro-3-pyridinyl)-1-methyl-N7,N7-dipropyl- (CA INDEX NAME)



RN 851887-85-9 CAPLUS  
CN Benzonitrile, 4-[[[7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]-3-ethyl- (CA INDEX NAME)




RN 851887-86-0 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(2,4-dimethoxy-6-methylphenyl)-1-methyl-N7,N7-dipropyl-, hydrochloride (1:?) (CA INDEX NAME)




●X HCl

RN 851887-87-1 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamine, N2-(2,4-dichloro-6-methylphenyl)-1-methyl-N7,N7-dipropyl-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 851887-88-2 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamine, N2-(2-chloro-6-(trifluoromethyl)-3-pyridinyl)-1-methyl-N7,N7-dipropyl-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 851887-89-3 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamine, N2-(2-chloro-4-(trifluoromethylphenyl)-1-methyl-N7,N7-dipropyl-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 851887-90-6 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamine, N2-(2-bromo-4-methoxy-6-methylphenyl)-1-methyl-N7,N7-dipropyl-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 851887-91-7 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxy-5-methylphenyl)-1-methyl-N7,N7-dipropyl-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl

RN 851887-92-8 CAPLUS  
 CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methylphenyl)-1-methyl-N7,N7-dipropyl-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 851887-93-9 CAPLUS




CN 1H-Benzimidazole-2,7-diamine, N7-(cyclopropylmethyl)-N7-[(2,4-dimethylphenyl)methyl]-1-methyl-N2-(2,4,6-trimethylphenyl)-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 851887-94-0 CAPLUS


CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-ethylphenyl)-N7,N7-dibutyl-1-methyl-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 851887-95-1 CAPLUS


CN 1H-Benzimidazole-2,7-diamine, N2-[4-chloro-2-methyl-6-(1-methylethyl)phenyl]-1-methyl-N7,N7-dipropyl-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 851887-96-2 CAPLUS


CN 1H-Benzimidazole-2,7-diamine, N7,N7-dibutyl-N2-(2,4-dimethoxy-6-methylphenyl)-1-methyl-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 851887-97-3 CAPLUS


CN 1H-Benzimidazole-2,7-diamine, N2-(2-bromo-4-methoxy-6-methylphenyl)-N7,N7-dibutyl-1-methyl-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 851887-99-5 CAPLUS


CN 1H-Benzimidazole-2,7-diamine, 1-(2-methoxyethyl)-N7,N7-dipropyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851888-00-1 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N7,N7-dipropyl-1-(2,2,2-trifluoroethyl)-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851888-01-2 CAPLUS  
CN 1H-Benzimidazole-1-ethanol, 7-(dipropylamino)-2-[(2,4,6-trimethylphenyl)amino]- (CA INDEX NAME)




RN 851888-02-3 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N7,N7-bis(cyclopropylmethyl)-1-methyl-N2-(2,4,6-trimethyl-3-pyridinyl)- (CA INDEX NAME)




RN 851888-03-4 CAPLUS  
CN Ethanone, 1-(7-(dipropylamino)-2-[(2,4,6-trimethylphenyl)amino]-1H-benzimidazol-1-yl)- (CA INDEX NAME)




RN 851888-04-5 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N7,N7-dibutyl-1-(2,2,2-trifluoroethyl)-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851888-05-6 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N7,N7-bis(cyclopropylmethyl)-1-(2,2,2-trifluoroethyl)-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)



RN 851888-06-7 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, 4-bromo-1-methyl-N7,N7-dipropyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 851888-12-5 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N7,N7-bis(2-methoxyethyl)-1-methyl-N2-(2,4,6-trimethyl-3-pyridinyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl


RN 851888-18-1 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methoxy-6-methylphenyl)-N7-bis(2-methoxyethyl)-1-methyl- (CA INDEX NAME)




RN 851888-20-5 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methoxy-6-methylphenyl)-N7-(2-methoxyethyl)-N7,7-dimethyl- (CA INDEX NAME)




RN 851888-21-6 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methoxy-6-methylphenyl)-N7-(2-methoxyethyl)-1-methyl-N7-(1-methylethyl)- (CA INDEX NAME)



RN 851888-24-9 CAPLUS  
CN Butanamide, 4-[[2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl] (1-methylethyl)amino]-N-methyl- (CA INDEX NAME)




RN 851888-25-0 CAPLUS  
CN Butanamide, 4-[[2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl] (1-methylethyl)amino]-N,N-dimethyl- (CA INDEX NAME)




RN 851888-26-1 CASUS

CN 1-Butanone, 4-[(2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl)](1-methylethyl)amino)-i-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 851888-27-2 CASUS

CN Butanamide, 4-[(2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl)](1-methylethyl)amino)-N,N-diethyl- (CA INDEX NAME)




RN 851888-28-3 CASUS

CN 1-Butanone, 4-[(2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl)](1-methylethyl)amino)-1-(4-morpholinyl)- (CA INDEX NAME)




RN 851888-29-4 CASUS

CN 1-Butanone, 4-[(2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl)](1-methylethyl)amino)-1-(1-piperidinyl)- (CA INDEX NAME)




RN 851888-30-7 CASUS

CN 1-Butanone, 4-[(2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl)](1-methylethyl)amino)-1-(4-thiomorpholinyl)- (CA INDEX NAME)




RN 851888-31-8 CAPLUS

CN 1-Butanone, 4-[[2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl](1-methylethyl)amino]-1-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 851888-32-9 CAPLUS

CN Acetamide, 2-[[2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl](1-methylethyl)amino]- (CA INDEX NAME)



RN 851888-33-0 CAPLUS


CN 1H-Benzimidazole-2,7-diamine, N7-(2-aminoethyl)-N2-(4-bromo-2-methoxy-6-methylphenyl)-1-methyl-N7-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 851888-35-2 CAPLUS


CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methoxy-6-methylphenyl)-N7-(2-(dimethylamino)ethyl)-1-methyl-N7-(1-methylethyl)-, hydrochloride (1:2) (CA INDEX NAME)



●x HCl


RN 851888-37-4 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxy-6-methylphenyl)-N7-(4-chlorophenyl)-1-methyl-N7-(1-methylethyl)-, hydrochloride (1:2) (CA INDEX NAME)




●<sub>x</sub> HCl

RN 851888-43-2 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-[(4-chloro-2-methoxy-6-methylphenyl)amino]-N7-[(4-chlorophenyl)-N7-(2,2-dimethylpropyl)-1-methyl-, hydrochloride (1:?) (CA INDEX NAME)




●<sub>x</sub> HCl

RN 851888-44-3 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-[(4-chloro-2-methoxy-6-methylphenyl)amino]-N7-[(4-chlorophenyl)-N7-(2-methoxyethyl)-1-methyl-, hydrochloride (1:?) (CA INDEX NAME)




●<sub>x</sub> HCl

RN 851888-45-4 CAPLUS  
CN Glycine, N-[2-[(4-chloro-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl]-N-(4-chlorophenyl)-, ethyl ester, hydrochloride (5CI) (CA INDEX NAME)



●<sub>x</sub> HCl


RN 851888-46-5 CAPLUS  
CN Acetamide, 2-[[2-[(4-chloro-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl]-(4-chlorophenyl)amino]-N,N-dimethyl-, hydrochloride (1:?) (CA INDEX NAME)



●X HCl

RN 851888-47-6 CAPLUS


CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxy-6-methylphenyl)-N7-(4-chlorophenyl)-N7-[2-(dimethylamino)ethyl]-1-methyl-, hydrochloride (1:2)  
(CA INDEX NAME)



●2 HCl


RN 851888-48-7 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxy-6-methylphenyl)-N7-(4-chlorophenyl)-1-methyl-N7-[(tetrahydro-3-furanyl)methyl]- (CA INDEX NAME)




RN 851888-49-8 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxy-6-methylphenyl)-N7-(4-methoxyphenyl)-1-methyl-N7-(1-methylethyl)- (CA INDEX NAME)



RN 851888-50-1 CAPLUS


CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxy-6-methylphenyl)-N7-(2-methoxyethyl)-N7-(4-methoxyphenyl)-1-methyl- (CA INDEX NAME)



RN 851888-52-3 CAPLUS


CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxy-6-methylphenyl)-N7-(4-

methoxyphenyl)-1-methyl-N-[(tetrahydro-2H-pyran-4-yl)methyl]- (CA INDEX NAME)




RN 851888-53-4 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxy-6-methylphenyl)-1-methyl-N7-(1-methylethyl)-N7-(5-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 851888-54-5 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxy-6-methylphenyl)-N7-(2-methoxyethyl)-1-methyl-N7-(5-methyl-2-pyridinyl)- (CA INDEX NAME)



RN 851888-55-6 CAPLUS


CN Acetamide, N-[2-[(4-chloro-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl]-[4-methoxyphenyl)-N,N-diethyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 851888-56-7 CAPLUS

CN Acetamide, N-[2-[(4-chloro-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl]-N-(4-chlorophenyl)-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 851888-58-9 CAPLUS


CN Acetamide, N-[2-[(4-chloro-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl]-N-(4-methoxyphenyl)- (CA INDEX NAME)






RN 851888-59-0 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methoxy-6-methylphenyl)-1-methyl-N7-(1-methylethyl)-N7-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)




RN 851888-61-4 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methoxy-6-methylphenyl)-1-methyl-N7-(1-methylethyl)-N7-[3-(methylsulfonyl)phenyl]- (CA INDEX NAME)



RN 851888-62-5 CAPLUS


CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methoxy-6-methylphenyl)-N7-ethyl-1-methyl-N7-(1-methylethyl)-, hydrochloride (1:2) (CA INDEX NAME)



●: HCl


RN 851888-63-6 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2,6-diethylphenyl)-1-methyl-N7,N7-dipropyl- (CA INDEX NAME)




RN 851888-64-7 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methoxy-6-methylphenyl)-N7,N7-dibutyl-1-methyl- (CA INDEX NAME)




RN 851888-65-8 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2,6-diethylphenyl)-1-methyl-N7,N7-dipropyl- (CA INDEX NAME)




RN 851888-66-9 CAPLUS

CN Butanoic acid, 4-[(cyclopropylmethyl)[1-methyl-2-[(2,4,6-trimethylphenylamino)-1H-benzimidazol-7-yl]amino]-, methyl ester (CA INDEX NAME)




RN 851888-67-0 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methoxy-6-methylphenyl)-N7,1-diethyl-1-methyl- (CA INDEX NAME)




RN 851888-68-1 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxy-6-methylphenyl)-1-methyl-N7,1-dipropyl- (CA INDEX NAME)




RN 851888-69-2 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N2-(3,4-dichloro-2-methoxy-6-methylphenyl)-1-methyl-N7,1-dipropyl- (CA INDEX NAME)




RN 851888-70-5 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methoxy-6-methylphenyl)-N7,1-dimethyl-1-methyl- (CA INDEX NAME)




RN 851888-71-6 CAPLUS


CN 1H-Benzimidazole-2,7-diamine, N7-ethyl-1-methyl-N7-(1-methylethyl)-N2-(2,4,6-trimethoxyphenyl)- (CA INDEX NAME)




RN 851888-72-7 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxy-6-methylphenyl)-N7-ethyl-1-methyl-N7-(1-methylethyl)- (CA INDEX NAME)




RN 851888-73-8 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxy-6-methylphenyl)-N7, N7-diethyl-1-methyl- (CA INDEX NAME)




RN 851888-74-9 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2,6-diethylphenyl)-N7, N7-diethyl-1-methyl- (CA INDEX NAME)




RN 851888-75-0 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2,6-diethylphenyl)-N7-ethyl-1-methyl-N7-(1-methylethyl)- (CA INDEX NAME)




RN 851888-77-2 CAPLUS  
CN Benzenemethanol, 5-chloro-2-[[7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]- (CA INDEX NAME)




RN 851888-78-3 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4-chloro-2-methoxyphenyl)-1-methyl-N7, N7-dipropyl- (CA INDEX NAME)




RN 851888-79-4 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(2-bromo-4-chlorophenyl)-1-methyl-N7, N7-dipropyl- (CA INDEX NAME)




RN 851888-81-8 CAPLUS  
CN Benzonitrile, 5-chloro-2-[[7-(dipropylamino)-1-methyl-1*H*-benzimidazol-2-yl]amino]- (CA INDEX NAME)




RN 851888-82-9 CAPLUS  
CN 1*H*-Benzimidazole-2,7-diamine, N2-[4-chloro-2-(methoxymethyl)phenyl]-1-methyl-N7,N7-dipropyl- (CA INDEX NAME)




RN 851888-83-0 CAPLUS  
CN 1*H*-Benzimidazole-2,7-diamine, 1-methyl-N7,N7-bis[2-(phenylmethoxy)ethyl]-N2-(2,4,6-trimethyl-3-pyridinyl)- (CA INDEX NAME)




RN 851888-84-1 CAPLUS  
CN 1*H*-Benzimidazole-2,4-diamine, N2-(4-chloro-2-ethoxyphenyl)-2,3-dihydro-1-methyl-N4,N4-dipropyl- (CA INDEX NAME)




RN 851888-85-2 CAPLUS  
CN 1*H*-Benzimidazole-2,7-diamine, 1-methyl-N2-(2,3,4,5,6-pentamethylphenyl)-N7,N7-dipropyl- (CA INDEX NAME)



RN 851888-86-3 CAPLUS  
CN 1*H*-Benzimidazol-2-amine, N-(4-bromo-2-methoxy-6-methylphenyl)-7-(2-ethyl-1-piperidinyl)-1-methyl- (CA INDEX NAME)




RN 851888-86-6 CAPLUS  
CN 1*H*-Benzimidazol-2-amine, N-(4-bromo-2-methoxy-6-methylphenyl)-1-methyl-7-(2-methyl-1-piperidinyl)- (CA INDEX NAME)




RN 851888-90-9 CAPLUS

CN 18-Benzimidazol-2-amine, N-(4-bromo-2-methoxy-6-methylphenyl)-7-(2-ethyl-1-pyrrolidyl)-1-methyl- (CA INDEX NAME)




RN 851888-91-0 CAPLUS

CN 18-Benzimidazol-2-amine, N-(4-bromo-2-methoxy-6-methylphenyl)-1-methyl-7-(2-methyl-1-pyrrolidyl)- (CA INDEX NAME)




RN 851888-92-1 CAPLUS

CN 18-Benzimidazol-2-amine, N-(4-bromo-2-methoxy-6-methylphenyl)-7-(3-ethyl-4-morpholinyl)-1-methyl- (CA INDEX NAME)




RN 851888-93-2 CAPLUS

CN 18-Benzimidazol-2-amine, N-(4-bromo-2-methoxy-6-methylphenyl)-1-methyl-7-(2-propyl-1-piperidyl)- (CA INDEX NAME)




RN 851888-94-3 CAPLUS

CN 18-Benzimidazol-2-amine, N-(4-bromo-2-methoxy-6-methylphenyl)-7-[2-(methoxymethyl)-1-piperidyl]-1-methyl- (CA INDEX NAME)



RN 851888-95-4 CAPLUS


CN 2,5-Pyridinediamine, N5-[7-(2-ethyl-1-piperidyl)-1-methyl-18-benzimidazol-2-yl]-N2,N2,4-trimethyl- (CA INDEX NAME)




RN 851888-96-5 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-18-benzimidazol-7-yl]-, methyl ester (CA INDEX NAME)







RN 851889-04-8 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-[2-(2-bromoethoxy)-4-chlorophenyl]-1-methyl-N7,N7-dipropyl- (CA INDEX NAME)




RN 851889-05-9 CAPLUS  
CN Acetonitrile, 2-[5-chloro-2-[[7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]phenoxy]- (CA INDEX NAME)




RN 851889-06-0 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-[2-(4-bromobutoxy)-4-chlorophenyl]-1-methyl-N7,N7-dipropyl- (CA INDEX NAME)



RN 851889-07-1 CAPLUS  
CN Pentanenitrile, 5-[5-chloro-2-[[7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]phenoxy]- (CA INDEX NAME)




RN 851889-09-3 CAPLUS  
CN Butanamide, 4-[5-chloro-2-[[7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]phenoxy]-N-methyl-, hydrochloride (1:2) (CA INDEX NAME)




● X HCl


RN 851889-10-6 CAPLUS  
CN Butanamide, 4-[5-chloro-2-[[7-(dipropylamino)-1-methyl-1H-benzimidazol-2-yl]amino]phenoxy]-N,N-dimethyl- (CA INDEX NAME)




RN 851889-19-5 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-[4-bromo-2-methoxy-6-methylphenyl]-1-methyl-N7-[2-(methylsulfonyl)phenyl]-N7-propyl- (CA INDEX NAME)



RN 851889-22-0 CAPLUS  
CN Benzonitrile, 4-[[2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl]] (1-methylethyl)amino]- (CA INDEX NAME)




RN 851889-28-6 CAPLUS  
CN Benzonitrile, 4-[[2-[(4-bromo-2-methoxy-6-methylphenyl)amino]-1-methyl-1H-benzimidazol-7-yl]] (1-methylethyl)amino]-2-methoxy- (CA INDEX NAME)




IT 851888-19-2, N-(4-Bromo-2-methoxy-6-methylphenyl)-1-methyl-1H-benzimidazole-2,7-diamine 851889-34-1, N-(4-Bromo-2-methoxy-6-methylphenyl)-N'-isopropyl-1-methyl-1H-

benzimidazole-2,7-diamine 851888-36-3, N'-(2-Aminoethyl)-N-(4-bromo-2-methoxy-6-methylphenyl)-N'-isopropyl-1-methyl-1H-benzimidazole-2,7-diamine  
EL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of nitrogen-containing fused heterocyclic compds. like benzimidazoles and benzothiazoles as CRP receptor antagonists with therapeutic potential)


RN 851888-19-2 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methoxy-6-methylphenyl)-1-methyl- (CA INDEX NAME)



RN 851888-34-1 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N2-(4-bromo-2-methoxy-6-methylphenyl)-1-methyl-N7-(1-methylethyl)- (CA INDEX NAME)



RN 851888-36-3 CAPLUS  
CN 1H-Benzimidazole-2,7-diamine, N7-(2-aminoethyl)-N2-(4-bromo-2-methoxy-6-methylphenyl)-1-methyl-N7-(1-methylethyl)- (CA INDEX NAME)




IT 851886-86-7P, N-Mesityl-1-methyl-1H-benzimidazole-2,7-diamine 851886-97-0P, N-Mesityl-1-methyl-N'-propyl-1H-benzimidazole-2,7-diamine  
EL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(preparation of nitrogen-containing fused heterocyclic compds. like benzimidazoles and benzothiazoles as CRE receptor antagonists with therapeutic potential)


RN 851886-86-7 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, 1-methyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)



RN 851886-97-0 CAPLUS

CN 1H-Benzimidazole-2,7-diamine, 1-methyl-N7-propyl-N2-(2,4,6-trimethylphenyl)- (CA INDEX NAME)



GS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

15 ANSWER 5 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:409508 CAPLUS <<LOGINID:20091110>>

DOCUMENT NUMBER: 142:463726

TITLE: Preparation of benzimidazolyls as TIE-2 tyrosine kinase inhibitors for the treatment of tumors  
Staehle, Wolfgang; Buchstaller, Hans-Peter; Jocznyk, Alfred; Rautenberg, Wilfried

PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany

SOURCE: PCT Int. Appl., 105 pp.

COLEM: FIXXND2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005042520	A1	20050512	WO 2004-EP11550	20041014 <-
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, EC, EE, EG, ES, FI, GE, GR, GU, HK, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LI, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, SN, SV, TH, TN, TR, TS, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

GE, GU, HK, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LI, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, SN, SV, TH, TN, TR, TS, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

DE 10349587 A1 20050525 DE 2003-10349587 20031024 <-  
AU 2004285643 A1 20050512 AU 2004-285643 20041014 <-  
CA 2543346 A1 20050512 CA 2004-2543346 20041014 <-  
EP 1675849 A1 20060705 EP 2004-765962 20041014 <-

R: AF, AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, EC, EE, EG, ES, FI, GE, GR, GU, HK, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LI, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, SN, SV, TH, TN, TR, TS, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

PRIORITY APPL. INFO.: DE 2003-10349587 A 20031024 <-  
WO 2004-EP11550 W 20041014 <-  
US 2006-577033 A3 20060424

OTHER SOURCE(S): MARPAT 142:463726


IT 851677-44-6P, (6-Nitro-1H-benzimidazol-2-yl)-[4-(pyridin-4-yl)oxy]phenylamine 851677-52-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THW (Therapeutic use); BIOU (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzimidazolyls as TIE-2 tyrosine kinase inhibitors for treatment of tumors)

RN 851677-44-6 CAPLUS


CN 1H-Benzimidazol-2-amine, 6-nitro-N-[4-(4-pyridinyloxy)phenyl]- (CA INDEX NAME)



RN 851677-52-6 CAPLUS

CN 1H-Benzimidazole-2,6-diamine, N2-[4-(4-pyridinyloxy)phenyl]- (CA INDEX NAME)





OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD  
(3 CITINGS)  
REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


15 ANSWER 6 OF 36 CAPLUS COPYRIGHT 2009 ACS ON STN  
ACCESSION NUMBER: 2005:76237 CAPLUS <LOGINID:20091110>  
DOCUMENT NUMBER: 142:176860  
TITLE: Preparation of thienopyrimidine derivatives as ErbB  
kinase inhibitors  
INVENTOR(S): Dickerson, Scott Howard; Emerson, Holly Kathleen;  
Hinkie, Kevin Wayne; Hornberger, Keith Robert;  
Sammond, Douglas McDord; Smith, Stephen; Stevens, Kirk  
Lawrence; Hubbard, Robert Dale; Petrov, Kimberly  
Glennon; Reno, Michael John; Uehling, David Edward;  
Waterson, Alex Gregory  
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA  
SOURCE: PCT Int. Appl., 241 pp.  
CODEN: FIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005007083	A2	20050127	WO 2004-US19410	20040617 <--
WO 2005007083	A3	20050421		

M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CE,  
CH, CO, CR, CU, CZ, DE, DK, DM, DO, EC, EE, ES, FI, GB, GD,  
GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, NZ, NA, NI,  
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SI, ST,  
TG, TM, TN, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: BW, GR, GM, KE, LS, MW, MG, NA, SD, SL, SZ, TZ, US, ZM, ZW, AM,  
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
SI, SK, TR, BF, BJ, CF, CG, CI, CN, GM, GW, GZ, GU, ML, MR, NE,  
NG, TD, TG

PRIORITY APPL. INFO.: US 2003-479324P P 20030618 <--  
OTHER SOURCE(S): CASREACT 142:176860; HARRAT 142:176860  
IT 833475-75-5R, N-(4-Fluorophenyl)-N'-[6-[[[(2R)-2-  
pyrrolidinyl]ethyl]thio][3,2-d]pyrimidin-4-yl]-1H-benzimidazole-2,5-  
diamine  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THD  
(Therapeutic use); BIOD (Biological study); PREP (Preparation); USSS  
(Uses)  
(drug candidate; preparation of thienopyrimidines as Erb kinase inhibitors)  
RN 833475-75-5 CAPLUS  
CN 1H-Benzimidazole-2,6-diamine, N2-(4-fluorophenyl)-N6'-[6-[(2-(2R)-2-  
pyrrolidinylethyl]thio)[3,2-d]pyrimidin-4-yl]- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD  
(3 CITINGS)  
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

15 ANSWER 7 OF 36 CAPLUS COPYRIGHT 2009 ACS ON STN  
ACCESSION NUMBER: 2005:14275 CAPLUS <LOGINID:20091110>  
DOCUMENT NUMBER: 142:114106  
TITLE: Preparation of heterocyclic compounds for preventing  
and treating disorders associated with excessive bone  
loss  
INVENTOR(S): Ono, Mitsunori; Sun, Lijun; Wada, Yumiko; Koya, Keiro;  
Nagai, Masazumi  
PATENT ASSIGNEE(S): Synta Pharmaceuticals Corp., USA  
SOURCE: PCT Int. Appl., 151 pp.  
CODEN: FIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005000404	A2	20050106	WO 2004-US17064	20040528 <--
WO 2005000404	A3	20050915		

M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CE,  
CH, CI, CH, CU, CZ, DE, DK, DM, DO, EC, EE, ES, FI, GB, GD,  
GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, NA, NI,  
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SI, ST,  
TG, TM, TN, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: BW, GR, GM, KE, LS, MW, MG, NA, SD, SL, SZ, TZ, US, ZM, ZW, AM,  
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
SI, SK, TR, BF, BJ, CF, CG, CI, CN, GM, GW, GZ, GU, ML, MR, NE,  
NG, TD, TG

AU 2004251641 A1 20050106 AU 2004-251641 20040528 <--  
CA 2527079 A1 20050106 CA 2004-2527079 20040528 <--  
EP 1626725 A2 20040222 EP 2004-776190 20040528 <--  
R: AT, BE, CH, DE, DM, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PG,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

JP 2007500241 T 20070111 JP 2006-533518 20040528 <--  
US 20080058297 A1 20080306 US 2006-561025 20060519 <--  
PRIORITY APPLN. INFO.: US 2003-47410P P 20030529 <--  
US 2003-474502P P 20030529 <--  
US 2003-474550P P 20030529 <--  
WO 2004-US17064 N 20040528 <--

OTHER SOURCE(S): MARRAT 142:114106


IT 682337-78-6P

RL: PAC (Pharmacological activity); SPW (Synthetic preparation); THD (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidines, triazines and purines for preventing and treating disorders associated with excessive bone loss)

RN 682337-78-6 CAPLUS

CN 1H-Benzimidazol-2-amine, 7-fluoro-N-(3-methylphenyl)-4,6-di-4-morpholinyl- (CA INDEX NAME)



GS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)  
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

15 ANSWER 8 OF 36 CAPLUS COPYRIGHT 2009 ACS ON STN

ACCESSION NUMBER: 2004:817883 CAPLUS <<LOIND:20091110>>  
DOCUMENT NUMBER: 141:332190

TITLE: Preparation of fused azoles such as 2,5-disubstituted benzimidazoles, benzoxazoles and benzothiazoles as kinase inhibitors

INVENTOR(S): Dipietro, Lucian V.; Harmange, Jean-Christophe; Askew, Benny C., Jr.; Elbaum, Daniel; Germain, Julie; Babgood, Gregory J.; Kim, Joseph L.; Patel, Vinod F.; Potashman, Michels; Van der Plas, Simon

PATENT ASSIGNEE(S): Amgen Inc., USA  
SOURCE: PCT Int. Appl., 289 pp.

CODEN: FFXNDZ

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004085425	A1	20041007	WO 2004-US8809	20040322 <--
M: AE, AG, AL, AM, AT, AU, AZ, BA, BG, BE, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FR, GB, GR, SE, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				

LV, LR, LS, LT, LU, LV, MA, MD, MG, MH, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RM: BW, GB, GM, KE, LS, MW, MZ, SD, SI, SZ, TG, US, ZM, ZW, AM, AZ, BY, EG, KE, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BE, BZ, CF, CG, CL, CM, GA, GN, GQ, GW, ML, MR, NE, NG, TD, TG

US 7531553 E2 20090512 US 2004-804915 20040319 <--  
US 20040209892 A1 20041021  
AU 2004223827 A1 20041007 AU 2004-223827 20040322 <--  
AU 2004223827 E2 20080306  
CA 2518909 A1 20041007 CA 2004-2518909 20040322 <--  
EP 1638954 A1 20060329 EP 2004-158050 20040322 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK  
JP 2006520805 T 20060914 JP 2006-507472 20040322 <--  
MX 2005010086 A 20060210 MX 2005-10086 20050921 <--  
US 2003-456691P P 20030321 <--

PRIORITY APPLN. INFO.: US 2004-804915 A 20040319 <--  
WO 2004-US8809 A 20040322 <--

OTHER SOURCE(S): MARRAT 141:332190

IT 1055984-37-6P 1055984-58-1P 1055984-62-7P


1055985-13-1P

RL: PAC (Pharmacological activity); PREP (Prophetic); SPW (Synthetic preparation); THD (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzimidazole, benzoxazole and benzothiazole derivs. as kinase inhibitors)


RN 1055984-37-6 CAPLUS

CN 3-Pyridinecarboxamide, 4-[[2-[(3,4-dichlorophenyl)amino]-1H-benzimidazol-6-yl]amino]-N-methyl- (CA INDEX NAME)




RN 1055984-58-1 CAPLUS


CN 1H-Benzimidazole-2,6-diamine, N2-(4-bromophenyl)-N6-(6,7-dimethoxy-4-quinolinyl)- (CA INDEX NAME)



RN 1055984-62-7 CAPLUS  
CN 18-Benzimidazole-2,6-diamine, N2-(4-cyclohexylphenyl)-N6-[2-(methylamino)-4-pyridindyl]- (CA INDEX NAME)



RN 1055985-13-1 CAPLUS  
CN 18-Benzimidazole-2,6-diamine, N2-(3-fluorophenyl)-N6-4-quinolinyl- (CA INDEX NAME)




OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)  
REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

15 ANSWER 9 OF 36 CAPLUS COPYRIGHT 2009 ACS ON STN  
ACCESSION NUMBER: 2004:51393 CAPLUS <<LOGIND:20091110>>  
DOCUMENT NUMBER: 141:71544  
TITLE: Preparation of substituted benzazoles as Raf kinase inhibitors  
INVENTOR(S): Amiri, Payman; Pantl, Wendy; Levine, Barry Haskell; Poon, Daniel J.; Ramurthy, Savichri; Benhowe, Paul A.; Subramanian, Sharadha; Sung, Leonard  
PATENT ASSIGNEE(S): USA  
SOURCE: U.S. Pat. Appl. Publ., 476 pp., Cont.-in-part of U.S. Pat. Appl. 2004 87,626.  
CODEN: USXACQ  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040122237	A1	20040624	US 2003-675927	20030929 <-
US 20040087626	A1	20040506	US 2003-405945	20030331 <-
US 7071216	B2	20060704		

AP	AI	20050414	AU 2004-277405	20040929 <-
CA 2533748	A1	20050414	CA 2004-2539748	20040929 <-
WO 2005032548	A1	20050414	WO 2004-US32161	20040929 <-
M: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BE, CA, CH, CE, CO, CR, CU, CY, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GE, GR, GU, HA, HE, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, ST, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GB, GM, KE, LS, MW, NG, NA, SD, SL, SE, SZ, TZ, UG, ZM, ZW, AG, BT, BG, GR, IL, IN, JP, KE, MG, MK, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, ST, SV, SY, TF, TG, TH, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
EP 167584	A1	20060705	EP 2004-789345	20040929 <-
R: AT, BE, BG, BR, CH, CY, CZ, DE, DK, ES, FR, GB, GR, HU, IL, IN, JP, KE, MG, PT, IE, SI, FI, RO, CY, TR, BG, CA, BE, HU, PL, SK				
BR 2004014908	A	20061107	BR 2004-14908	20040929 <-
CN 1913884	A	20070214	CN 2004-80032677	20040929 <-
JP 2007507428	T	20070329	JP 2006-528331	20040929 <-
US 20070299039	A1	20071227	US 2005-262939	20061118 <-
MX 2006003435	A	20060620	MX 2006-3435	20060327 <-
JP 2006193533	A	20060727	JP 2006-96143	20060330 <-
KR 2006089232	A	20060808	KR 2006-706470	20060403 <-
IN 2006XN0838	A	20070413	IN 2006-KN838	20060405 <-
ZA 2006003418	A	20070725	ZA 2006-3418	20060428 <-
PRIORITY APPL. INFO.:				
			US 2002-36906P	P 20020329 <-
			US 2003-405945	A2 20030331 <-
			JP 2003-579810	A3 20030331 <-
			US 2003-675927	A 20030929 <-
			WO 2004-US32161	W 20040929 <-

OTHER SOURCE(S): MARPAT 141:71544  
IT 611220-17-8P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THF (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(Raf kinase inhibitor; preparation of substituted benzazoles as Raf kinase inhibitors for treatment of cancer)  
RN 611220-17-8 CAPLUS  
CN 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-1H-benzimidazol-6-yl]amino]-N-methyl- (CA INDEX NAME)



IT 611225-93-5P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(intermediates; preparation of substituted benzazoles as Raf kinase inhibitors for treatment of cancer)  
RN 611225-93-5 CAPLUS  
CN 18-Benzimidazole-2,6-diamine, N2-(4-bromophenyl)- (CA INDEX NAME)




OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD  
(19 CITINGS)

15 ANSWER 10 OF 36 CAPLUS COPYRIGHT 2009 ACS ON STM  
ACCESSION NUMBER: 2004:355045 CAPLUS <<LOGINDID:20091110>>  
DOCUMENT NUMBER: 140:357119  
TITLE: Preparation of amino morpholinopurine derivatives for treating interleukin-12 overproduction-related disorders  
INVENTOR(S): Sun, Lijun; Ono, Mitsunori; Wada, Yumiko; Ying, Weiwen; Frawioka, Teresa; Kostik, Elena  
PATENT ASSIGNEE(S): Synta Pharmaceuticals Corp., USA  
SOURCE: PCT Int. Appl., 68 pp.  
CODEN: PEXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004035740	A2	20040429	WO 2003-US32546	20031014 <--
WO 2004035740	A3	20041216		
M: AG, AG, AL, AM, AT, AU, AC, BA, BB, BG, BR, BY, BE, CA, CH, CN, CO, CR, CU, CE, DE, DK, DM, DZ, EC, EE, ES, FI, GE, GD, GG, GH, GR, GW, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, ME, NO, NZ, OM, PG, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TM, TN, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GM, GM, HE, LS, MW, ME, SD, SL, SZ, TG, UG, ZM, AM, AZ, BY, BG, CZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CE, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, ML, PT, RO, SE, SI, SK, TR, BF, BO, CF, CG, CI, CM, GA, GN, GQ, GW, ML, NE, NG, SN, TD, TG				
CA 2502356	A1	20040429	CA 2003-2502356	20031014 <--
AU 2003289142	A1	20040504	AU 2003-284142	20031014 <--
US 20040198725	A1	20041007	US 2003-686505	20031014 <--
US 7122465	B2	20061017		
EP 1556140	A2	20050727	EP 2003-776373	20031014 <--
R: AG, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CE, EE, HU, SK				
JP 2004502723	T	20040302	JP 2004-542265	20031014 <--
US 20070027151	A1	20070201	US 2006-542363	20061003 <--
US 7410930	B2	20060812		
PRIORITY APPLN. INFO.:				
US 2002-41984P P 20021015 <--				
US 2003-686505 A1 20031014 <--				
WO 2003-US32546 W 20031014 <--				


OTHER SOURCE(S): HARPAT 140:357119  
IT 682337-79-6P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THH (Therapeutic use); BDL (Biological study); FRP (Preparation); USES

(Uses)  
(preparation of amino morpholinopurine derivs. for treating interleukin-12 overprod.-related disorders)  
RN 682337-78-6 CAPLUS  
CN 1H-Benzimidazol-2-amine, 7-fluoro-N-(3-methylphenyl)-4,6-di-4-morpholinyl- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD  
(2 CITINGS)  
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 36 CAPLUS COPYRIGHT 2009 ACS ON STM  
ACCESSION NUMBER: 2004:6498 CAPLUS <<LOGINDID:20091110>>  
DOCUMENT NUMBER: 141:136262  
TITLE: Molecular Modeling and Design of Radiolabelled Complexes for Melanoma Diagnosis  
AUTHOR(S): Tuttle, C. T. Tell; Seabrook, Shane A.; Wise, Lauren E.; Katsifis, Andrew; Knott, Robert B.; Yates, Brian F.  
CORPORATE SOURCE: School of Chemistry, University of Tasmania, Hobart, TAS 7001, Australia  
SOURCE: Australian Journal of Chemistry (2004), 57(1), 87-96  
CODEN: AJCHAS; ISSN: 0004-9425  
PUBLISHER: CSIRO Publishing  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 727409-66-4  
RL: BSU (Biological study, unclassified); FRP (Properties); BDL (Biological study)  
(Integrin receptor-binding)  
RN 727409-66-4 CAPLUS  
CN 1-Alanine, 3-[[[7-nitro-2-(phenylamino)-1H-benzimidazol-5-yl]carbonyl]amino]-N-(phenylsulfonyl)- (CA INDEX NAME)  
Absolute stereochemistry.




OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD  
(2 CITINGS)  
REFERENCE COUNT: 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

15 ANSWER 12 OF 36 CAPLUS COPYRIGHT 2009 ACS ON SUN  
ACCESSION NUMBER: 2003:796477 CAPLUS <<LOGIND:20091110>>  
DOCUMENT NUMBER: 139:307759  
TITLE: Preparation of substituted benzazoles as Raf kinase  
inhibitors  
INVENTOR(S): Benhowe, Paul A.; Ramurthy, Savithri; Amiri, Payman;  
Levine, Barry Haskell; Poon, Daniel J.; Subramanian,  
Sharadha; Sura, Leonard; Pantl, Wendy  
PATENT ASSIGNEE(S): Chiron Corporation, USA  
SOURCE: PCT Int. Appl., 259 pp.  
CODEN: FEXX2D  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003082272	A1	20031009	WO 2003-US10117	20030331 <-
M: AG, AG, AL, AM, AT, AU, A2, BA, BB, BG, BR, BY, BE, CA, CH, CN, CC, CR, CU, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GN, GU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, ME, NI, NO, NZ, OM, PG, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TM, TN, TR, TT, TG, UA, US, UZ, VC, VN, YU, ZA, ZH, ZW				
RW: GA, GB, HE, LS, MW, NZ, SD, SI, ST, TO, UG, ZM, ZW, AM, AG, BY, BG, CZ, MD, RU, TG, TM, AT, BE, BG, BG, CH, CY, DE, DK, DE, ES, FI, FR, GB, GR, HU, IS, IT, LU, MC, ML, PT, RO, SE, SI, SG, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GJ, GW, ML, MR, NE, SN, TD, TG				
CA 2480638	A1	20031009	CA 2003-2480638	20030331 <-
AU 200326221	A1	20031013	AU 2003-22621	20030331 <-
AU 200326221	B2	20080529		
EP 1493311	A1	20050126	EP 2003-745683	20030331 <-
EP 1493311	B1	20051104		
R: AG, BE, CH, DE, DK, ES, FR, GB, GR, IN, LI, LU, NL, SE, MC, PT, IE, SI, IT, IV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HG, SK				
BR 200300854	A	20050222	BR 2003-9854	20030331 <-
CN 1655779	A	20050817	CN 2003-812193	20030331 <-
CN 100515419	C	20080722		
JP 2005529089	T	20050929	JP 2003-573910	20030331 <-
NZ 535985	A	20070427	NZ 2003-535985	20030331 <-
AP 1913	A	20080103	AP 2004-3161	20030331 <-
IN 2004KM01433	A	20051230	IN 2004-KM433	20040527 <-
MX 2004009541	A	20050125	MX 2004-9541	20040529 <-

NO 2004004617 A 20041228 NO 2004-4617 20041026 <-  
ZA 2004008386 A 20060531 ZA 2004-8386 20060308 <-  
JP 2006193533 A 20060727 JP 2006-96143 20060330 <-  
PRIORITY APPLN. INFO.: US 2002-369066P P 20020329 <-  
JP 2003-573910 A3 20030331 <-  
WO 2003-US10117 W 20030331 <-

OTHER SOURCE(S): MARPAT 139:307759  
IT 611220-17-8P  
RU: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
RU (preparation of substituted benzazoles as Raf kinase inhibitors)  
RU 611220-17-8 CAPLUS  
CN 2-Pyridinecarboxamides, 4-[[2-[(4-bromophenyl)amino]-1H-benzimidazol-6-yl]amino]-N-methyl- (CA INDEX NAME)



IT 611225-93-5P  
RU: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
RU (preparation of substituted benzazoles as Raf kinase inhibitors)  
RU 611225-93-5 CAPLUS  
CN 1H-Benzimidazole-2,6-diamine, N2-(4-bromophenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 19 THERE ARE 19 CAPLUS RECORDS THAT CITE THIS  
RECORD (22 CITINGS)  
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

15 ANSWER 13 OF 36 CAPLUS COPYRIGHT 2009 ACS ON SUN  
ACCESSION NUMBER: 2003:715473 CAPLUS <<LOGIND:20091110>>  
DOCUMENT NUMBER: 135:246042  
TITLE: Preparation of benzimidazolylamino arylamino  
pyridine TIE-2 and/or VEGFR inhibitors and their use  
as angiogenesis inhibitors  
INVENTOR(S): Chamberlain, Stanley Daves; Cheng, Hui; Emerson,  
Holly Kathleen; Johnson, Neil W.; Nailor, Kristan  
Elizabeth; Samond, Douglas Mccord; Semones, Marcus  
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA  
SOURCE: PCT Int. Appl., 253 pp.

DOCUMENT TYPE:  
 LANGUAGE:  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


CODEN: F1XXD2

Patent  
 English

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003074515	A1	20030912	WO 2003-US6022	20030228 <-
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BT, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, EC, EE, ES, FI, GE, GR, GU, HK, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PA, PE, PG, PH, PI, PT, RO, RU, SC, SD, SE, SG, SI, SJ, TH, TM, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZH, ZW				
RW: GG, GM, HE, LS, MW, ND, SD, SL, SS, SZ, TG, UG, ZM, ZW, AM, AZ, BY, BG, BR, BU, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, TF, BT, CT, CG, CL, CW, GA, GN, GT, GW, ML, NE, NG, SN, TD, TG				
CA 2471505	A1	20030912	CA 2003-2471505	20030228 <-
AU 2003220970	A1	20030916	AU 2003-220970	20030228 <-
EP 1487824	A1	20041222	EP 2003-743709	20030228 <-
EP 1487824	B1	20070620		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005524668	T	20050818	JP 2003-572963	20030228 <-
AT 365165	T	20070715	AT 2003-743709	20030228 <-
ES 2250479	T3	20080216	ES 2003-743709	20030228 <-
MX 2004000458	A	20041206	MX 2004-8458	20040901 <-
US 20050234083	A1	20051020	US 2004-506447	20040901 <-
US 7338959	B2	20080304		
PRIORITY APPL. INFO.:			US 2002-360741P	P 20020301 <-
			WO 2003-US6022	W 20030228 <-


OTHER SOURCE(S): MARPAT 133:246042

IT 596132-35-3P, [1-Methyl-5-[methyl(2-[(3-sulfamoylphenyl)amino]pyrimidin-4-yl)amino]-1H-benzimidazol-2-yl]phenylcarbamate acid tert-butyl ester hydrochloride  
 596132-38-6P, [1-Methyl-5-[methyl(2-[(4-methyl-3-sulfamoylphenyl)amino]pyrimidin-4-yl)amino]-1H-benzimidazol-2-yl]phenylcarbamate acid tert-butyl ester hydrochloride  
 596132-67-1P, [5-[[2-[[4-(methanesulfonyl)methylphenyl]amino]pyrimidin-4-yl]methyl]amino]-1-methyl-1H-benzimidazol-2-yl] (4-methoxyphenyl)carbamate acid tert-butyl ester  
 596132-70-6P, (4-Methoxyphenyl) [1-methyl-5-[methyl(2-[[4-sulfamoylmethylphenyl]amino]pyrimidin-4-yl)amino]-1H-benzimidazol-2-yl]carbamate acid tert-butyl ester  
 596132-73-9P, [5-[[2-[[3-(methanesulfonyl)methylphenyl]amino]pyrimidin-4-yl]methyl]amino]-1-methyl-1H-benzimidazol-2-yl] (4-methoxyphenyl)carbamate acid tert-butyl ester  
 596132-76-2P, [5-[[2-[[4-(1-methanesulfonyl)ethylphenyl]amino]pyrimidin-4-yl]methyl]amino]-1-methyl-1H-benzimidazol-2-yl] (4-methoxyphenyl)carbamate acid tert-butyl ester  
 R1: RAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); TEU (Therapeutic use); B10L (Biological study); PRCP (Preparation); RACT (Reactant or reagent); USDS (Uses)  
 (drug candidate; preparation of benzimidazolylamino arylamino pyrimidines  
 TIE-2 and/or VEGFR inhibitors and their use as angiogenesis inhibitors)  
 RN 596132-35-3 CAPLUS  
 CN Carbanic acid, 5-[[2-[[3-(aminosulfonyl)phenyl]amino]-4-pyrimidinyl]methylamino]-1-methyl-1H-benzimidazol-2-yl]phenyl-, 1,1-dimethylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 596132-38-6 CAPLUS  
 CN Carbanic acid, 5-[[2-[[3-(aminosulfonyl)-4-methylphenyl]amino]-4-pyrimidinyl]methylamino]-1-methyl-1H-benzimidazol-2-yl]phenyl-, 1,1-dimethylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 596132-67-1 CAPLUS  
 CN Carbanic acid, (4-methoxyphenyl) [1-methyl-5-[methyl(2-[[4-[[methylsulfonyl)methylphenyl]amino]-4-pyrimidinyl]amino]-1H-benzimidazol-2-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596132-70-6 CAPLUS  
 CN Carbanic acid, 5-[[2-[[4-[[aminosulfonyl)methylphenyl]amino]-4-pyrimidinyl]methylamino]-1-methyl-1H-benzimidazol-2-yl] (4-methoxyphenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RM 595132-73-9 CAPJUS

CN Carbanic acid, (4-methoxyphenyl)[1-methyl-5-[methyl(2-[[3-(methanesulfonyl)methyl]phenyl]amino)-4-pyrimidinyl]amino]-1H-benzimidazol-2-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RM 595132-75-2 CAPJUS

CN Carbanic acid, (4-methoxyphenyl)[1-methyl-5-[methyl(2-[[4-[[1-(methylsulfonyl)ethyl]phenyl]amino)-4-pyrimidinyl]amino]-1H-benzimidazol-2-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 595131-19-2P, N'-Methyl-1-methyl-N'-[2-[[4-[[methylamino]phenyl]phenyl]amino]pyrimidin-4-yl]-1-methyl-1H-benzimidazole-2,5-diamine 595131-20-5P 595132-36-4P

, 3-[[4-[[methyl(1-methyl-2-phenylamino)-1H-benzimidazol-5-yl]amino]pyrimidin-2-yl]amino]benzenesulfonamide 595132-37-5P, 3-[[4-[[methyl(1-methyl-2-phenylamino)-1H-benzimidazol-5-yl]amino]pyrimidin-2-yl]amino]benzenesulfonamide trifluoroacetate 595132-39-7P, N'-[2-[[3-[[methylamino]phenyl]amino]pyrimidin-4-yl]-1-methyl-N'-methyl-1H-benzimidazole-2,5-diamine 595132-40-0P 595132-41-1P, 1-[[4-[[4-[[methyl(1-methyl-2-phenylamino)-1H-

benzimidazol-5-yl]amino]pyrimidin-2-yl]amino]phenyl]methanesulfonamide 595132-42-2P, 4-[[4-[[methyl(1-methyl-2-phenylamino)-1H-benzimidazol-5-yl]amino]pyrimidin-2-yl]amino]phenyl]methanesulfonamide trifluoroacetate 595132-43-3P, Methanesulfonic acid 4-[[4-[[methyl(1-methyl-2-phenylamino)-1H-benzimidazol-5-yl]amino]pyrimidin-2-yl]amino]phenyl ester 595132-44-4P, Methanesulfonic acid 4-[[4-[[methyl(1-methyl-2-phenylamino)-1H-benzimidazol-5-yl]amino]pyrimidin-2-yl]amino]phenyl ester trifluoroacetate 595132-45-5P, 3-[[4-[[2-[[4-Fluorophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]amino]pyrimidin-2-yl]amino]benzenesulfonamide 595132-46-6P, 3-[[4-[[2-[[4-Fluorophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]amino]pyrimidin-2-yl]amino]benzenesulfonamide trifluoroacetate 595132-47-7P, 5-[[4-[[2-[[4-Fluorophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide 595132-48-8P, 5-[[4-[[2-[[4-Fluorophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide trifluoroacetate 595132-49-9P, N'-[4-[[4-Fluorophenyl]-N'-[2-[[4-[[methylamino]phenyl]phenyl]amino]pyrimidin-4-yl]-1-methyl-N'-methyl-1H-benzimidazole-2,5-diamine 595132-50-2P 595132-51-3P, 1-[[4-[[4-[[2-[[4-Fluorophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]amino]phenyl]methanesulfonamide 595132-52-4P, 4-[[4-[[2-[[4-Fluorophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]amino]phenyl]methanesulfonamide 595132-53-5P, Methanesulfonic acid 4-[[4-[[2-[[4-Fluorophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]amino]pyrimidin-2-yl]amino]phenyl ester 595132-54-6P, Methanesulfonic acid 4-[[4-[[2-[[4-Fluorophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]amino]pyrimidin-2-yl]amino]phenyl ester trifluoroacetate 595132-55-7P, Methanesulfonic acid 3-[[4-[[2-[[4-Fluorophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]amino]pyrimidin-2-yl]amino]phenyl ester 595132-56-8P, Methanesulfonic acid 3-[[4-[[2-[[4-Fluorophenyl]amino]-1-methyl-1H-benzimidazol-5-yl]amino]pyrimidin-2-yl]amino]phenyl ester trifluoroacetate 595132-57-9P, N'-[2-[[4-[[methylamino]phenyl]phenyl]amino]pyrimidin-4-yl]-1-methyl-N'-methyl-N'-p-tolyl-1H-benzimidazole-2,5-diamine 595132-58-1P 595132-60-4P, 1-[[4-[[4-[[2-[[4-tert-Butylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]amino]phenyl]methanesulfonamide 595132-61-5P, 4-[[4-[[2-[[4-tert-Butylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]amino]phenyl]methanesulfonamide trifluoroacetate 595132-62-6P, 3-[[4-[[2-[[4-tert-Butylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]amino]phenyl]methanesulfonamide 595132-63-7P, 3-[[4-[[2-[[4-tert-Butylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]amino]phenyl]methanesulfonamide trifluoroacetate 595132-64-8P, 5-[[4-[[2-[[4-tert-Butylphenyl]amino]-1-methyl-1H-benzimidazol-5-yl]amino]phenyl]methanesulfonamide 595132-65-9P, N'-[4-tert-Butylphenyl]-N'-[2-[[4-[[methylamino]phenyl]phenyl]amino]pyrimidin-4-yl]-1-methyl-N'-methyl-1H-benzimidazole-2,5-diamine 595132-66-0P 595132-69-3P 595132-74-0P, N'-[2-[[3-[[methylamino]phenyl]phenyl]amino]pyrimidin-4-yl]-N'-[4-methoxyphenyl]-1-methyl-N'-methyl-1H-benzimidazole-2,5-diamine 595132-75-1P 595132-77-3P, N'-[2-[[4-[[1-[[methylamino]ethyl]phenyl]amino]pyrimidin-4-yl]-N'-[4-

methoxyphenyl)-1-methyl-N'-methyl-1H-benzimidazole-2,5-diamine  
 596132-78-4F 596132-79-5F,  
 N'-[2-[3-[(1-(Methanesulfonyl)ethyl]phenyl]amino]pyrimidin-4-yl]-N-(4-methoxyphenyl)-1-methyl-N'-methyl-1H-benzimidazole-2,5-diamine  
 596132-80-8F 596133-05-0F,  
 1-Methyl-N'-[2-[[4-[(Methanesulfonyl)methyl]phenyl]amino]pyrimidin-4-yl]-N'-methyl-N-(4-trifluoromethylphenyl)-1H-benzimidazole-2,5-diamine  
 596133-06-1F, 1-Methyl-N'-[2-[[4-[(Methanesulfonyl)methyl]phenyl]amino]pyrimidin-4-yl]-N'-methyl-N-(3-chlorophenyl)-1H-benzimidazole-2,5-diamine 596133-07-2F,  
 1-Methyl-N'-[2-[[4-[(Methanesulfonyl)methyl]phenyl]amino]pyrimidin-4-yl]-N'-methyl-N-(4-chlorophenyl)-1H-benzimidazole-2,5-diamine  
 596133-08-3F, 1-Methyl-N'-[2-[[4-[(Methanesulfonyl)methyl]phenyl]amino]pyrimidin-4-yl]-N'-methyl-N-(2,4-dichlorophenyl)-1H-benzimidazole-2,5-diamine 596133-09-4F,  
 1-Methyl-N'-[2-[[4-[(Methanesulfonyl)methyl]phenyl]amino]pyrimidin-4-yl]-N'-methyl-N-(2,5-dichlorophenyl)-1H-benzimidazole-2,5-diamine  
 596133-10-7F, 1-Methyl-N'-[2-[[4-[(Methanesulfonyl)methyl]phenyl]amino]pyrimidin-4-yl]-N'-methyl-N-(2-chloro-4-(trifluoromethyl)phenyl)-1H-benzimidazole-2,5-diamine  
 596133-11-0F, 1-Methyl-N'-[2-[[4-[(Methanesulfonyl)methyl]phenyl]amino]pyrimidin-4-yl]-N'-methyl-N-(2-chloro-5-(trifluoromethyl)phenyl)-1H-benzimidazole-2,5-diamine  
 596133-12-9F, 1-Methyl-N'-[2-[[4-[(Methanesulfonyl)methyl]phenyl]amino]pyrimidin-4-yl]-N'-methyl-N-(4-morpholinophenyl)-1H-benzimidazole-2,5-diamine 596133-13-4F,  
 1-Methyl-N'-[2-[[4-[(Methanesulfonyl)methyl]phenyl]amino]pyrimidin-4-yl]-N'-methyl-N-(3-fluorophenyl)-1H-benzimidazole-2,5-diamine  
 596133-14-1F, 1-Methyl-N'-[2-[[4-[(Methanesulfonyl)methyl]phenyl]amino]pyrimidin-4-yl]-N'-methyl-N-(2-chloro-4-fluorophenyl)-1H-benzimidazole-2,5-diamine  
 596133-16-3F, 1-Methyl-N'-[2-[[4-[(Methanesulfonyl)methyl]phenyl]amino]pyrimidin-4-yl]-N'-methyl-N-(4-chloro-2-fluorophenyl)-1H-benzimidazole-2,5-diamine 596133-17-4F,  
 1-Methyl-N'-[2-[[4-[(Methanesulfonyl)methyl]phenyl]amino]pyrimidin-4-yl]-N'-methyl-N-(2-chloro-5-fluorophenyl)-1H-benzimidazole-2,5-diamine  
 596133-18-5F, 1-Methyl-N'-[2-[[4-[(Methanesulfonyl)methyl]phenyl]amino]pyrimidin-4-yl]-N'-methyl-N-(2-fluorophenyl)-1H-benzimidazole-2,5-diamine 596133-20-3F,  
 1-Methyl-N'-[2-[[4-[(Methanesulfonyl)methyl]phenyl]amino]pyrimidin-4-yl]-N'-methyl-N-(2-fluorophenyl)-1H-benzimidazole-2,5-diamine  
 596133-21-0F, 1-Methyl-N'-[2-[[4-[(Methanesulfonyl)methyl]phenyl]amino]pyrimidin-4-yl]-N'-methyl-N-(2-fluoro-5-(trifluoromethyl)phenyl)-1H-benzimidazole-2,5-diamine  
 596133-26-5F, 4-[[4-[[Methyl[1-methyl-2-[[4-trifluoromethyl]phenyl]amino]-1H-benzimidazol-5-yl]amino]pyrimidin-2-yl]amino]benzenesulfonamide 596133-35-8F,  
 N'-[2-[[4-[(Methanesulfonyl)methyl]phenyl]amino]pyrimidin-4-yl]-1-methyl-N'-methyl-N-(3-trifluoromethylphenyl)-1H-benzimidazole-2,5-diamine  
 596135-00-1F, Phenyl[1-Methyl-5-[methyl[2-[(3-sulfamoyl)phenyl]amino]pyrimidin-4-yl]amino]-1H-benzimidazol-2-yl]carbamate  
 596135-01-2F,  
 (Phenyl)[1-Methyl-5-[methyl[2-[(4-methyl-3-sulfamoyl)phenyl]amino]pyrimidin-4-yl]amino]-1H-benzimidazol-2-yl]carbamate  
 596135-02-3F, 5-[[4-[(2-[(4-tert-butylphenyl)amino]-1-methyl-1H-benzimidazol-5-yl)]methyl]amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide  
 RL: PAC (Pharmacological activity); SPK (Synthetic preparation); THU (Therapeutic use); BTOL (Biological study); FRFP (Preparation); USES


(Uses)  
 (drug candidate; preparation of benzimidazolylamino arylamino pyrimidine TIE-2 and/or VEGFR inhibitors and their use as angiogenesis inhibitors)  
 RN 596131-79-2 CAPLUS  
 CN 1H-Benzimidazole-2,5-diamine, N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]-N2-phenyl-, (CA INDEX NAME)



RN 596131-00-5 CAPLUS  
 CN 1H-Benzimidazole-2,5-diamine, N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]-N2-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 596131-79-2  
 CMF C27 R27 M7 O2 S




CM 2

CRN 76-05-1  
 CMF C2 H F3 O2



RN 596132-36-4 CAPLUS  
 CN Benzenesulfonamide, 3-[[4-[[methyl[1-methyl-2-(phenylamino)-1H-benzimidazol-5-yl]amino]-2-pyrimidinyl]amino]- (CA INDEX NAME)






RN 596132-37-5 CAPLUS  
CN Benzenesulfonamide, 3-[[4-[methyl[1-methyl-2-(phenylamino)-1H-benzimidazol-5-yl]amino]-2-pyrimidinyl]amino]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 596132-36-4  
CMF C25 H24 N8 O2 S




CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 596132-39-7 CAPLUS  
CN 1H-Benzimidazole-2,5-diamine, N5,1-dimethyl-N5-[2-[[4-methyl-3-(methylsulfonyl)phenyl]amino]-4-pyrimidinyl]-N2-phenyl- (CA INDEX NAME)



RN 596132-40-0 CAPLUS  
CN 1H-Benzimidazole-2,5-diamine, N5,1-dimethyl-N5-[2-[[4-methyl-3-(methylsulfonyl)phenyl]amino]-4-pyrimidinyl]-N2-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 596132-39-7  
CMF C27 H27 N7 O2 S




CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 596132-41-1 CAPLUS  
CN Benzenemethanesulfonamide, 4-[[4-[methyl[1-methyl-2-(phenylamino)-1H-benzimidazol-5-yl]amino]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 596132-42-2 CAPLUS  
CN Benzenemethanesulfonamide, 4-[[4-[methyl[1-methyl-2-(phenylamino)-1H-benzimidazol-5-yl]amino]-2-pyrimidinyl]amino]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 596132-41-1  
CMF C26 H26 N8 O2 S




CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 596132-43-3 CAPLUS  
CN Phenol, 4-[[[4-methyl-1-methyl-2-(phenylamino)-1H-benzimidazol-5-yl]amino]-2-pyrimidinyl]amino]-, 1-methanesulfonate (CA INDEX NAME)



RN 596132-44-4 CAPLUS  
CN Phenol, 4-[[[4-methyl-1-methyl-2-(phenylamino)-1H-benzimidazol-5-yl]amino]-2-pyrimidinyl]amino]-, 1-methanesulfonate, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 596132-42-3  
CMF C26 H25 N7 O3 S




CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 596132-45-5 CAPLUS  
CN Benzenesulfonamide, 3-[[[4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]methylamino]-2-pyrimidinyl]amino]-1-methyl-1H-benzimidazol-5-yl]methylamino]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 596132-46-6 CAPLUS  
CN Benzenesulfonamide, 3-[[[4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]methylamino]-2-pyrimidinyl]amino]-1-methyl-1H-benzimidazol-5-yl]methylamino]-2-pyrimidinyl]amino]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 596132-45-5  
CMF C25 H23 F3 N8 O2 S




CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 596132-47-7 CAPLUS  
CN Benzenesulfonamide, 5-[[4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]methylamino]-2-pyrimidinyl]amino]-2-methyl- (CA INDEX NAME)



RN 596132-48-8 CAPLUS  
CN Benzenesulfonamide, 5-[[4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]methylamino]-2-pyrimidinyl]amino]-2-methyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 596132-47-7  
CMF C26 H25 F H8 O2 S




CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 596132-49-9 CAPLUS  
CN 1H-Benzimidazole-2,5-diamine, N2-(4-fluorophenyl)-N5,1-dimethyl-N5-[2-[[4-(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 596132-50-2 CAPLUS  
CN 1H-Benzimidazole-2,5-diamine, N2-(4-fluorophenyl)-N5,1-dimethyl-N5-[2-[[4-(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 596132-49-9  
CMF C27 H26 F H7 O2 S




CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 596132-51-3 CAPLUS  
CN Benzenesulfonamide, 4-[[4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]methylamino]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 596132-52-4 CAPLUS  
CN Benzenesulfonamide, 4-[[4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]methylamino]-2-pyrimidinyl]amino]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 596132-51-3  
CMF C26 H25 F N8 O2 S




CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 596132-53-5 CAPLUS  
CN Phenol, 4-[[4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]methylamino]-2-pyrimidinyl]amino]-, 1-methanesulfonate (CA INDEX NAME)



RN 596132-54-6 CAPLUS  
CN Phenol, 4-[[4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]methylamino]-2-pyrimidinyl]amino]-, 1-methanesulfonate, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 596132-53-5  
CMF C26 H24 F N7 O3 S




CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 596132-55-7 CAPLUS  
CN Phenol, 3-[[4-[[2-[(4-fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]methylamino]-2-pyrimidinyl]amino]-, 1-methanesulfonate (CA INDEX NAME)



RN 596132-56-8 CAPLUS  
CN Phenol, 3-[[4-[[2-[[4-(fluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]methanimino-2-pyrimidinyl]amino]-, 1-methanesulfonate, 2,2,2-trifluoroacetate (1:1)] (CA INDEX NAME)

CM 1

CFW 596132-55-7  
CMF C26 H24 F N7 O3 S




CM 2

CFW 76-05-1  
CMF C2 H F3 O2




RN 596132-58-0 CAPLUS  
CN 1H-Benzimidazole-2,5-diamine, N5,1-dimethyl-N2-(4-methylphenyl)-N5-[2-[[4-[(methanesulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 596132-59-1 CAPLUS  
CN 1H-Benzimidazole-2,5-diamine, N5,1-dimethyl-N2-(4-methylphenyl)-N5-[2-[[4-[(methanesulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CFW 596132-58-0  
CMF C28 H29 N7 O2 S




CM 2

CFW 76-05-1  
CMF C2 H F3 O2




RN 596132-60-4 CAPLUS  
CN Benzenemethanesulfonamide, 4-[[4-[[2-[[4-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]methanimino-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 596132-61-5 CAPLUS  
CN Benzenemethanesulfonamide, 4-[[4-[[2-[[4-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]methanimino-2-pyrimidinyl]amino]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CRN 596132-60-4  
CMF C30 H34 N8 O2 S



CRN 76-05-1  
CMF C2 H E3 02

CC1=NC2=CC=CC=C2N(C)C1=NC3=CC=CC=C3N3C(=O)S(=O)(=O)C4=CC=CC=C4


CRN 596132-62-6  
CMF C29 H32 N8 O2 S



CRN 76-05-1  
CME C2 H F3 02

Cc1ccc(cc1C(=O)N2C=NC=C2N(C)C3C=CC=C4C(=C3)N(C)C=C4N(C)C5=CC=CC=C5C)S(=O)(=O)N

RN 596132-65-9 CAPLUS  
CN 1H-Benzimidazole-2,5-diamine, N2-[4-(1,1-dimethylethyl)phenyl]-N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]]-(CA INDEX NAME)




RN 596132-66-0 CAFLUS

CN 1H-Benzimidazole-2,5-diamine, N2-[4-(1,1-dimethylethyl)phenyl]-N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) {CA INDEX NAME}

CM 1

CNW 596132-65-9

CMF C31 E35 W7 O2 S



CM 2

CNW 76-05-1

CMF C2 H F3 O2




RN 596132-69-3 CAFLUS

CN 1H-Benzimidazole-2,5-diamine, N2-(4-methoxyphenyl)-N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) {CA INDEX NAME}

CM 1

CNW 596132-68-2

CMF C28 E29 W7 O3 S



CM 2


CNW 76-05-1

CMF C2 H F3 O2



RN 596132-74-0 CAFLUS

CN 1H-Benzimidazole-2,5-diamine, N2-(4-methoxyphenyl)-N5,1-dimethyl-N5-[2-[[3-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 596132-75-1 CAFLUS

CN 1H-Benzimidazole-2,5-diamine, N2-(4-methoxyphenyl)-N5,1-dimethyl-N5-[2-[[3-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) {CA INDEX NAME}

CM 1

CNW 596132-74-0

CMF C28 E29 W7 O3 S




CM 2

CFW 76-05-1  
CMF C2 H F3 O2



RN 596132-77-3 CAPLUS

CM 1H-Benzimidazole-2,5-diamine, N2-(4-methoxyphenyl)-N5,1-dimethyl-N5-[2-[[4-[1-(methylsulfonyl)ethyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 596132-78-4 CAPLUS

CM 1H-Benzimidazole-2,5-diamine, N2-(4-methoxyphenyl)-N5,1-dimethyl-N5-[2-[[4-[1-(methylsulfonyl)ethyl]phenyl]amino]-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CFW 596132-77-3  
CMF C29 H31 N7 O3 S




CM 2

CFW 76-05-1  
CMF C2 H F3 O2



RN 596132-79-5 CAPLUS

CM 1H-Benzimidazole-2,3-diamine, N2-(4-methoxyphenyl)-N5,1-dimethyl-N5-[2-[[3-[1-(methylsulfonyl)ethyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 596132-80-8 CAPLUS

CM 1H-Benzimidazole-2,5-diamine, N2-(4-methoxyphenyl)-N5,1-dimethyl-N5-[2-[[3-[1-(methylsulfonyl)ethyl]phenyl]amino]-4-pyrimidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CFW 596132-79-5  
CMF C29 H31 N7 O3 S






CM 2

CMW 76-05-1  
CMF C2 H F3 O2




RN 596133-05-0 CAPLUS

CM 1H-Benzimidazole-2,5-diamine, N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]-N2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 596133-06-1 CAPLUS

CM 1H-Benzimidazole-2,5-diamine, N2-(3-chlorophenyl)-N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 596133-07-2 CAPLUS

CM 1H-Benzimidazole-2,5-diamine, N2-(4-chlorophenyl)-N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 596133-08-3 CAPLUS

CM 1H-Benzimidazole-2,5-diamine, N2-(2,4-dichlorophenyl)-N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 596133-09-4 CAPLUS

CM 1H-Benzimidazole-2,5-diamine, N2-(2,5-dichlorophenyl)-N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 596133-10-7 CAPLUS

CM 1H-Benzimidazole-2,5-diamine, N2-(2-chloro-4-(trifluoromethyl)phenyl)-N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 596133-11-8 CAPLUS

CN 1H-Benzimidazole-2,5-diamine, N2-[2-chloro-5-(trifluoromethyl)phenyl]-N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 596133-12-9 CAPLUS

CN 1H-Benzimidazole-2,5-diamine, N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]-N2-[4-(morpholinyl)phenyl]- (CA INDEX NAME)




RN 596133-13-0 CAPLUS

CN 1H-Benzimidazole-2,5-diamine, N2-(3-fluorophenyl)-N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 596133-14-1 CAPLUS

CN 1H-Benzimidazole-2,5-diamine, N2-(2,4-difluorophenyl)-N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 596133-15-2 CAPLUS

CN 1H-Benzimidazole-2,5-diamine, N2-(2-chloro-4-fluorophenyl)-N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 596133-16-3 CAPLUS


CN 1H-Benzimidazole-2,5-diamine, N2-(4-chloro-2-fluorophenyl)-N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 596133-17-4 CAPLUS  
CN 1H-Benzimidazole-2,5-diamine, N2-(2-chloro-5-fluorophenyl)-N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 596133-18-5 CAPLUS  
CN 1H-Benzimidazole-2,5-diamine, N2-(2-fluoro-4-methylphenyl)-N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 596133-20-9 CAPLUS  
CN 1H-Benzimidazole-2,5-diamine, N2-(2-fluorophenyl)-N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 596133-21-0 CAPLUS  
CN 1H-Benzimidazole-2,5-diamine, N2-[2-fluoro-5-(trifluoromethyl)phenyl]-N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 596133-26-5 CAPLUS  
CN Benzenesulfonamide, 4-[[4-[methyl(1-methyl-2-[[4-(trifluoromethyl)phenyl]amino]-1H-benzimidazol-5-yl]amino]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 596133-35-6 CAPLUS  
CN 1H-Benzimidazole-2,5-diamine, N5,1-dimethyl-N5-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]-N2-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 596135-00-1 CAPJUS

CN Carbanic acid, [5-[[2-[[3-(aminosulfonyl)phenyl]amino]-4-pyrimidinyl]methylamino]-1-methyl-1H-benzimidazol-2-yl]phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596135-01-2 CAPJUS

CN Carbanic acid, [5-[[2-[[3-(aminosulfonyl)-4-methylphenyl]amino]-4-pyrimidinyl]methylamino]-1-methyl-1H-benzimidazol-2-yl]phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 596135-02-3 CAPJUS

CN Benzenesulfonamide, 5-[[4-[[2-[[4-(1,1-dimethylethyl)phenyl]amino]-1-methyl-1H-benzimidazol-5-yl]methylamino]-2-pyrimidinyl]amino]-2-methyl- (CA INDEX NAME)



IT 596130-89-1R, tert-Butyl


[5-[(2-chloropyrimidin-4-yl)(methyl)amino]-1-methyl-1H-benzimidazol-2-yl](phenyl)carbamate 596130-90-4P,  
4-Methyl-5-nitro-1H-benzimidazol-2-amine 596130-91-5P  
tert-Butyl (1-methyl-5-nitro-1H-benzimidazol-2-yl)phenylcarbamate 596130-92-6P, tert-Butyl (5-amino-1-methyl-1H-benzimidazol-2-yl)phenylcarbamate 596130-93-7P, tert-Butyl [5-[(2-chloropyrimidin-4-yl)amino]-1-methyl-1H-benzimidazol-2-yl](phenyl)carbamate 596131-27-0P,  
[5-[(2-chloropyrimidin-4-yl)(methyl)amino]-1-methyl-1H-benzimidazol-2-yl](4-fluorophenyl)carbanic acid tert-butyl ester 596131-28-1P, (4-Fluorophenyl)(1-methyl-5-nitro-1H-benzimidazol-2-yl)amine 596131-29-2P, (5-Amino-1-methyl-1H-benzimidazol-2-yl)(4-fluorophenyl)carbanic acid tert-butyl ester 596131-30-5P, [5-[(2-chloropyrimidin-4-yl)amino]-1-methyl-1H-benzimidazol-2-yl](4-fluorophenyl)carbanic acid tert-butyl ester 596131-31-6P, [5-[(2-chloropyrimidin-4-yl)(methyl)amino]-1-methyl-1H-benzimidazol-2-yl]-p-tolylcarbanic acid tert-butyl ester 596131-32-7P, (1-Methyl-5-nitro-1H-benzimidazol-2-yl)-p-tolylamine 596131-33-8P, (1-Methyl-5-nitro-1H-benzimidazol-2-yl)-p-tolylcarbanic acid tert-butyl ester 596131-34-9P, (5-Amino-1-methyl-1H-benzimidazol-2-yl)-p-tolylcarbanic acid tert-butyl ester 596131-35-0P, [5-[(2-chloropyrimidin-4-yl)amino]-1-methyl-1H-benzimidazol-2-yl]-p-tolylcarbanic acid tert-butyl ester 596131-36-1P, (4-tert-Butylphenyl)[5-[(2-chloropyrimidin-4-yl)(methyl)amino]-1-methyl-1H-benzimidazol-2-yl]carbanic acid tert-butyl ester 596131-37-2P, (4-tert-Butylphenyl)(1-methyl-5-nitro-1H-benzimidazol-2-yl)amine 596131-38-3P, (4-tert-Butylphenyl)(1-methyl-5-nitro-1H-benzimidazol-2-yl)carbanic acid tert-butyl ester 596131-39-4P, (5-Amino-1-methyl-1H-benzimidazol-2-yl)(4-tert-butylphenyl)carbanic acid tert-butyl ester 596131-40-7P, (4-tert-Butylphenyl)[5-[(2-chloropyrimidin-4-yl)amino]-1-methyl-1H-benzimidazol-2-yl]carbanic acid tert-butyl ester 596131-41-8P, N'-(2-chloropyrimidin-4-yl)-N-(4-methoxyphenyl)-1-methyl-N'-methyl-1H-benzimidazole-2,5-diamine 596131-42-9P, (4-Methoxyphenyl)(1-methyl-5-nitro-1H-benzimidazol-2-yl)amine 596131-43-0P, (4-Methoxyphenyl)(1-methyl-5-nitro-1H-benzimidazol-2-yl)carbanic acid tert-butyl ester 596131-44-1P, (5-Amino-1-methyl-1H-benzimidazol-2-yl)(4-methoxyphenyl)carbanic acid tert-butyl ester 596131-45-2P, [5-[(2-chloropyrimidin-4-yl)amino]-1-methyl-1H-benzimidazol-2-yl](4-methoxyphenyl)carbanic acid tert-butyl ester 596131-46-3P, [5-[(2-chloropyrimidin-4-yl)(methyl)amino]-1-methyl-1H-benzimidazol-2-yl](4-methoxyphenyl)carbanic acid tert-butyl ester 596131-74-7P, (1-Methyl-5-nitro-1H-benzimidazol-2-yl)(4-fluorophenyl)carbanic acid tert-butyl ester 596133-27-6P, (1-Methyl-5-nitro-1H-benzimidazol-2-yl)(3-trifluoromethylphenyl)amine

596133-23-8P, (1-Methyl-5-nitro-1H-benzimidazol-2-yl) (3-trifluoromethylphenyl) carbamic acid 1,1-dimethylethyl ester  
 596133-31-2P, (5-amino-1-methyl-1H-benzimidazol-2-yl) (3-trifluoromethylphenyl) carbamic acid 1,1-dimethylethyl ester  
 596133-33-4P, [5-[(2-Chloropyrimidin-4-yl) (methyl)amino]-1-methyl-1H-benzimidazol-2-yl] (3-trifluoromethylphenyl) carbamic acid 1,1-dimethylethyl ester  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzimidazolyamino arylamino pyrimidine TIE-2 and/or VEGFR inhibitors and their use as angiogenesis inhibitors)


RN 596130-89-1 CAPLUS

CN Carbamic acid, [5-[(2-chloro-4-pyrimidinyl)methylamino]-1-methyl-1H-benzimidazol-2-yl]phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596130-90-4 CAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-5-nitro-N-phenyl- (CA INDEX NAME)




RN 596130-91-5 CAPLUS

CN Carbamic acid, (1-methyl-5-nitro-1H-benzimidazol-2-yl)phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596130-92-6 CAPLUS

CN Carbamic acid, (5-amino-1-methyl-1H-benzimidazol-2-yl)phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596130-93-7 CAPLUS

CN Carbamic acid, [5-[(2-chloro-4-pyrimidinyl)amino]-1-methyl-1H-benzimidazol-2-yl]phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-27-0 CAPLUS

CN Carbamic acid, [5-[(2-chloro-4-pyrimidinyl)methylamino]-1-methyl-1H-benzimidazol-2-yl] (4-fluorophenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-28-1 CAPLUS

CN 1H-Benzimidazol-2-amine, N-(4-fluorophenyl)-1-methyl-5-nitro- (CA INDEX NAME)




RN 596131-29-2 CAPLUS

CN Carbamic acid, (5-amino-1-methyl-1H-benzimidazol-2-yl) (4-fluorophenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-30-5 CAPLUS

CN Carbamic acid, [5-[(2-chloro-4-pyrimidinyl)amino]-1-methyl-1H-benzimidazol-2-yl] (4-fluorophenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-31-6 CAPLUS

CN Carbamic acid, [5-[(2-chloro-4-pyrimidinyl)methylamino]-1-methyl-1H-benzimidazol-2-yl] (4-methylphenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-32-7 CAPLUS

CN 1H-Benzimidazol-2-amine, 1-methyl-N-(4-methylphenyl)-5-nitro- (CA INDEX NAME)




RN 596131-33-8 CAPLUS

CN Carbamic acid, (1-methyl-5-nitro-1H-benzimidazol-2-yl) (4-methylphenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-34-9 CAPLUS

CN Carbamic acid, (5-amino-1-methyl-1H-benzimidazol-2-yl) (4-methylphenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-35-0 CAPLUS

CN Carbamic acid, [5-[(2-chloro-4-pyrimidinyl)amino]-1-methyl-1H-benzimidazol-2-yl] (4-methylphenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-36-1 CAPLUS


CN Carbamic acid, [5-[(2-chloro-4-pyrimidinyl)methylamino]-1-methyl-1H-benzimidazol-2-yl] [(4-{1,1-dimethylethyl}phenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)]




RN 596131-37-2 CAPLUS  
CN 1H-Benzimidazol-2-amine, N-(4-(1,1-dimethylethyl)phenyl)-1-methyl-5-nitro- (CA INDEX NAME)




RN 596131-38-3 CAPLUS  
CN Carbamic acid, [4-(1,1-dimethylethyl)phenyl](1-methyl-5-nitro-1H-benzimidazol-2-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-39-4 CAPLUS  
CN Carbamic acid, (5-amino-1-methyl-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-40-7 CAPLUS  
CN Carbamic acid, [5-[(2-chloro-4-pyrimidinyl)amino]-1-methyl-1H-benzimidazol-2-yl][4-(1,1-dimethylethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-41-8 CAPLUS  
CN 1H-Benzimidazole-2,5-diamine, N5-(2-chloro-4-pyrimidinyl)-N2-(4-methoxyphenyl)-N5,1-dimethyl- (CA INDEX NAME)




RN 596131-42-9 CAPLUS  
CN 1H-Benzimidazol-2-amine, N-(4-methoxyphenyl)-1-methyl-5-nitro- (CA INDEX NAME)




RN 596131-43-0 CAPLUS  
CN Carbamic acid, (4-methoxyphenyl)(1-methyl-5-nitro-1H-benzimidazol-2-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-44-1 CAPLUS  
CN Carbamic acid, (5-amino-1-methyl-1H-benzimidazol-2-yl)(4-methoxyphenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-45-2 CAPLUS  
CN Carbamic acid, [5-[(2-chloro-4-pyrimidinyl)amino]-1-methyl-1H-benzimidazol-2-yl] (4-methoxyphenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-46-3 CAPLUS  
CN Carbamic acid, [5-[(2-chloro-4-pyrimidinyl)methylamino]-1-methyl-1H-benzimidazol-2-yl] (4-methoxyphenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596131-74-7 CAPLUS  
CN Carbamic acid, (4-fluorophenyl) [(1-methyl-5-nitro-1H-benzimidazol-2-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 596133-27-6 CAPLUS  
CN 1H-Benzimidazol-2-amine, 1-methyl-5-nitro-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 596133-29-8 CAPLUS  
CN Carbamic acid, (1-methyl-5-nitro-1H-benzimidazol-2-yl) [3-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 596133-31-2 CAPLUS  
CN Carbamic acid, (5-amino-1-methyl-1H-benzimidazol-2-yl) [3-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 596133-33-4 CAPLUS  
CN Carbamic acid, [5-[(2-chloro-4-pyrimidinyl)methylamino]-1-methyl-1H-benzimidazol-2-yl] [3-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)






OS.CITING REF COUNT: 16 THERE ARE 16 CAPLUS RECORDS THAT CITE THIS  
REFERENCE COUNT: 3 RECORD (17 CITINGS)  
THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


15 ANSWER 14 OF 36 CAPLUS COPYRIGHT 2009 ACS on STW  
ACCESSION NUMBER: 2002:142711 CAPLUS <<LOGIND:20091110>>  
DOCUMENT NUMBER: 136:200200  
TITLE: Preparation of imidazoquinazolinones as inhibitors of tyrosine kinases  
INVENTOR(S): Snow, Roger John; Gao, Donghong A.; Goldberg, Daniel R.; Hammach, Abdelhakim; Kuznich, Daniel; Morwick, Tina Marie; Moss, Neil; Prokopowicz, Anthony S., III; Seillian, Robert D.; Takahashi, Hidenori  
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA  
SOURCE: PCT Int. Appl., 147 pp.  
CODEN: FIKXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002014319	A2	20020221	WO 2001-US24390	20010802 <--
WO 2002014319	A3	20020801		
M: CA, JP, MX PM: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
CA 2417635	A1	20020221	CA 2001-2417635	20010802 <--
CA 2417635	C	20080205		
US 20020119975	A1	20020829	US 2001-921510	20010802 <--
US 6489328	B2	20021203		
EP 1309596	A2	20030514	EP 2001-957425	20010802 <--
EP 1309596	B1	20080206		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
JP 2004506636	T	20040304	JP 2002-519459	20010802 <--
AT 385498	T	20080215	AT 2001-957425	20010802 <--
ES 2299401	T3	20080601	ES 2001-957425	20010802 <--
US 20030207902	A1	20031106	US 2002-271222	20021015 <--
US 6844435	B2	20050118		
MX 2003001306	A	20031015	MX 2003-1306	20030211 <--
PRIORITY APPLN. INFO.:				
US 2000-224724P F 20000811 <--				
US 2001-921510 A3 20010802 <--				
WO 2001-US24390 W 20010802 <--				


OTHER SOURCE(S): MARPAT 136:200200  
IT 400784-57-0P 400784-58-9P 400784-59-0P  
400784-60-3P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(Preparation of imidazoquinazolinones as inhibitors of tyrosine kinases)  
RN 400784-57-3 CAPLUS  
CN 1H-Benzimidazole-7-carbonitrile, 6-amino-2-[(2,6-dichlorophenyl)amino]-1-methyl- (CA INDEX NAME)




RN 400784-58-3 CAPLUS  
CN Acetamide, N-[7-cyano-2-[(2,6-dichlorophenyl)amino]-1-methyl-1H-benzimidazole-6-yl]- (CA INDEX NAME)



RN 400784-59-0 CAPLUS  
CN 1H-Benzimidazole-7-carboxanide, 6-amino-2-[(2,6-dichlorophenyl)amino]-1-methyl- (CA INDEX NAME)



RN 400784-60-3 CAPLUS  
CN 1H-Benzimidazole-7-carboxanide, 2-[(2,6-dichlorophenyl)amino]-1-methyl-6-[[12-propen-1-ylamino]thioxomethyl]amino]- (CA INDEX NAME)




CS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)  
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

15 ANSWER 15 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2000:699780 CAPLUS <<LOGINDID:20091110>>  
DOCUMENT NUMBER: 134:52473  
TITLE: Syntheses and Properties of 1-Methyl-3-phenylaminobenzimidazolium Salts, Models of DNA Adducts of N7-Arylamino deoxyguanosine Salt  
AUTHOR(S): Maiya, Toyoo; Fujiwara, Tomoko; Kohda, Kohfuku  
CORPORATE SOURCE: Faculty of Pharmaceutical Sciences, Nagoya City University, Mizuho-ku Nagoya, 467-8603, Japan  
SOURCE: Chemical Research in Toxicology (2000), 13(10), 993-1001  
COCODE: COTOCC; ISSN: 0893-228X  
PUBLISHER: American Chemical Society  
DOCUMENT TYPE: Journal  
LANGUAGE: English


IT 313486-00-0P  
RI: FRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and methylation)

RN 313486-00-9 CAPLUS  
CN 1H-Benzimidazol-1-amine, 6-nitro-N-phenyl- (CA INDEX NAME)



IT 313486-01-0P  
RI: FRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (preparation of)

RN 313486-01-0 CAPLUS  
CN 1H-Benzimidazolium, 1-methyl-5-nitro-3-(phenylamino)-, iodide (1:1) (CA INDEX NAME)



CS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD


(4 CITINGS)

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

15 ANSWER 16 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1999:511140 CAPLUS <<LOGINDID:20091110>>  
DOCUMENT NUMBER: 131:157771  
TITLE: Preparation of five-membered, benzo-condensed heterocycles as antithrombotics  
INVENTOR(S): Ries, Uwe; Haezel, Norbert; Milm, Gerhard; Prieske, Henning; Binder, Klaus; Stassen, Jean Marie; Wiesen, Wolfgang; Zimmermann, Rainer  
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma Kg, Germany  
SOURCE: PCT Int. Appl., 250 pp.  
COCODE: FIXXND  
LANGUAGE: Patent  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9940072	A1	19990812	WO 1999-EP537	19990128 <-
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GR, GM, GU, HU, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NC, NZ, NL, NO, NU, OI, PG, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RM: GB, GM, KE, LS, MW, SE, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SF, BJ, CF, CG, CI, CM, CA, CN, GH, GW, ML, MR, NE, SN, TD, TG				
DE 19804085	A1	19990805	DE 1998-19804085	19980203 <-
DE 19834325	A1	20000217	DE 1998-19834325	19980730 <-
CA 2319494	A1	19990812	CA 1999-2319494	19990128 <-
AU 9927201	A	19990823	AU 1999-27201	19990128 <-
EP 1050165	A1	20001220	EP 1999-907437	19990128 <-
R: AT, BG, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LV, LT, FI, RO				
JP 2002502844	T	20020129	JP 2000-530502	19990128 <-
MX 2000005785	A	20010123	MX 2000-5785	20000512 <-
PRIORITY APPL. INFO.: DE 1998-19804085 A 19980203 <- DE 1998-19834325 A 19980730 <- WO 1999-EP537 W 19990128 <-				

OTHER SOURCE(S): MARPAT 131:157771  
IT 236416-21-0P 236416-22-1P 236416-27-0P  
RI: RAC (Biological activity or effector, except adverse); BST (Biological study, unclassified); SPN (Synthetic preparation); BTOL (Biological study); PREP (Preparation) (preparation of five-membered benzo-condensed heterocycles as antithrombotics)  
RN 236416-21-0 CAPLUS  
CN Glycine, N-[2-[[4-(aminomethyl)phenylamino]-1-methyl-1H-benzimidazol-5-yl]-5-(8-quinolinsulfonyl)-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 236416-22-1 CAPLUS  
CN Glycine, N-[2-[(4-(aminomethyl)phenyl)amino]-1-methyl-1H-benzimidazol-5-yl]-N-(8-quinolylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 236416-27-6 CAPLUS  
CN Benzenecarboximidamide, 4-[[1-methyl-5-[(8-quinolylsulfonyl)amino]-1H-benzimidazol-2-yl]amino]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

IT 236417-44-0P 236417-45-1P 236417-46-2P  
236417-47-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)  
(preparation of five-membered benzo-condensed heterocycles as antithrombotics)


RN 236417-44-0 CAPLUS  
CN Benzonitrile, 4-[(1-methyl-5-nitro-1H-benzimidazol-2-yl)amino]- (CA INDEX NAME)




RN 236417-45-1 CAPLUS  
CN Benzonitrile, 4-[(5-amino-1-methyl-1H-benzimidazol-2-yl)amino]- (CA INDEX NAME)



RN 236417-46-2 CAPLUS  
CN 8-Quinolinesulfonamide, N-[2-[(4-cyanophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]- (CA INDEX NAME)



RN 236417-47-3 CAPLUS  
CN Glycine, N-[2-[(4-cyanophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]-N-(8-quinolylsulfonyl)-, ethyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS RECORD (17 CITINGS)

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

15 ANSWER 17 OF 36 CAPLUS COPYRIGHT 2009 ACS on SWH

ACCESSION NUMBER: 1999:505930 CAPLUS <<LOGINDID::20091110>>

DOCUMENT NUMBER: 131:157761

TITLE: 5-Membered heterocyclic condensed benzo derivatives, their preparation, and their use as drugs

INVENTOR(S): Ries, Dwe; Haevel, Norbert; Mihm, Gerhard; Priepke, Henning; Binder, Klaus; Stassen, Jean Marie; Wienen, Wolfgang; Zimmermann, Rainer

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany

SOURCE: Ger. Offen., 84 pp.

CODEN: GRXXEX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19804085	A1	19950805	DE 1998-19804085	19980203 <-
CA 2319494	A1	19950812	CA 1999-2319494	19990128 <-
WO 9940072	A1	19950812	WO 1999-EP537	19990128 <-
M: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CE, CH, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GR, HM, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TG, TM, TR, TT, UA, US, UG, UY, VU, ZW				
RW: GE, GM, HE, LS, MW, SD, SZ, US, ZW, AT, BE, CE, CT, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SF, BG, CF, CG, CI, CM, GM, GN, GW, ML, MR, NE, SN, TD, TG				
AU 5927201	A	19950823	AU 1999-27201	19990128 <-
EP 1060166	A1	20001220	EP 1999-907437	19990128 <-
R: AR, BE, CE, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002502844	F	20020129	JP 2000-530562	19990128 <-
US 6114532	A	20000905	US 1999-243200	19990202 <-
MX 200005785	A	20010123	MX 2000-5785	20000512 <-
PRIORITY APPLN. INFO.:				
DE 1998-19804085 A 19980203 <-				
US 1998-77694P F 19980312 <-				
DE 1998-19834325 A 19980730 <-				
WO 1999-EP537 W 19990128 <-				
OTHER SOURCE(S): MARPAT 131:157761				
IT 236416-21-0P 236417-44-0P 236417-45-1P				
236417-46-2P 236417-47-3P				
RL: RCT (Reactant); SPW (Synthetic preparation); PREP (Preparation); RACT				

(Reactant or reagent)  
(preparation and antithrombotic activity of  
benzimidazolymethylbenzimidines)

RN 236416-21-0 CAPLUS


CN Glycine, N-[2-[(4-(aminomethyl)phenyl)amino]-1-methyl-1H-benzimidazol-5-yl]-N-(8-quinolinylsulfonyl)-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● RCL


RN 236417-44-0 CAPLUS

CN Benzonitrile, 4-[(1-methyl-5-nitro-1H-benzimidazol-2-yl)amino]- (CA INDEX NAME)




RN 236417-45-1 CAPLUS

CN Benzonitrile, 4-[(5-amino-1-methyl-1H-benzimidazol-2-yl)amino]- (CA INDEX NAME)




RN 236417-46-2 CAPLUS

CN 8-Quinolinesulfonamide, N-[2-[(4-cyanophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]- (CA INDEX NAME)



RN 236417-47-3 CAPLUS

CN Glycine, N-[2-[(4-cyanophenyl)amino]-1-methyl-1H-benzimidazol-5-yl]-N-(8-quinolinylsulfonyl)-, ethyl ester (CA INDEX NAME)




IT 236416-22-1F 237750-43-5P

RL: SPW (Synthetic preparation); PREP (Preparation)  
(preparation and antithrombotic activity of  
benzimidazolymethylbenzamidines)

RN 236416-22-1 CAPLUS


CN Glycine, N-[2-[(4-(aminomethyl)phenyl)amino]-1-methyl-1H-benzimidazol-5-yl]-N-(8-quinolinylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 237750-43-5 CAPLUS

CN Benzenecarboximidamide, 4-[[1-methyl-5-[(8-quinolinylsulfonyl)amino]-1H-benzimidazol-2-yl]amino]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD  
(10 CITINGS)

15 ANSWER 18 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:806527 CAPLUS <<LOGIND:20091110>>

DOCUMENT NUMBER: 130:81512

TITLE: Preparation of benzoxazole, benzimidazole, and  
benzothiazole compounds inhibiting production of  
cytokine in type-2 helper T cell

INVENTOR(S): Tokunaga, Teruhisa; Fujita, Kazushi; Nagata, Ryu;  
Ochi, Hiroshi; Matanabe, Takasasa; Nakatani, Tomosuke  
PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Co., Ltd., Japan; Sumitomo  
Chemical Co., Ltd.

SOURCE: Jpn. Kokai Tokkyo Koho, 336 pp.

CODEN: JCKXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 16330369	A	19981215	JP 1997-225679	19970806 <-
PRIORITY APPLN. INFO.:			JP 1997-102481	A 19970404 <-
OTHER SOURCE(S):			MARPAT 130:81512	

IT 218621-62-4P

RL: BMC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); SPW (Synthetic preparation); TEU (Therapeutic use);  
BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of benzoxazole, benzimidazole, and benzothiazole compds.  
inhibiting production of cytokine in type-2 helper T (Th2) cell for  
treatment diseases related to hyperfunction of Th2 cells)


RN 218621-62-6 CAPLUS

CN Phenol, 5-nitro-2-[(6-nitro-1H-benzimidazol-2-yl)amino]- (CA INDEX NAME)




OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD  
(3 CITINGS)


15 ANSWER 19 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1992:511052 CAPLUS <<LOGINID:20091110>>  
DOCUMENT NUMBER: 117:111052  
ORIGINAL REFERENCE NO.: 117:1939a,1936a  
TITLE: EPR study of nitroxyl radicals of substituted  
5-anilinothiazoles, 5-anilinothiazoles, and  
2-anilinothiazoles  
AUTHOR(S): Omelka, Ladislav; Meske, Michael; Cholvad, Vladimir;  
Svetlik, Jan; Schulz, Manfred  
CORPORATE SOURCE: Dep. Phys. Chem., Slovak Tech. Univ., Bratislava, 812  
37, Czech.  
SOURCE: Collection of Czechoslovak Chemical Communications (1992), 57(5), 1065-71  
CODEN: CCCCXK; ISSN: 0010-0765  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 143017-91-8 143017-92-9  
RL: FRP (Properties)  
(ESR of)  
RN 143017-91-8 CAPLUS  
CN Nitroxide, 5-nitro-1H-benzimidazol-2-yl phenyl (9CI) (CA INDEX NAME)




RN 143017-92-9 CAPLUS  
CN Nitroxide, 4-methoxyphenyl 5-nitro-1H-benzimidazol-2-yl (9CI) (CA INDEX NAME)



IT 86601-34-5 86601-36-7  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(oxidation of, with peroxy radical, nitroxide from)  
RN 86601-34-5 CAPLUS  
CN 1H-Benzimidazol-2-amine, 6-nitro-N-phenyl- (CA INDEX NAME)



RN 86601-36-7 CAPLUS  
CN 1H-Benzimidazol-2-amine, N-(4-methoxyphenyl)-6-nitro- (CA INDEX NAME)




OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD  
(2 CITINGS)

15 ANSWER 20 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1991:449687 CAPLUS <<LOGINID:20091110>>  
DOCUMENT NUMBER: 115:49687  
ORIGINAL REFERENCE NO.: 115:8633a,8636a  
TITLE: Preparation of aminobenzimidazoles as dual inhibitors  
of lipoxigenase and cyclooxygenase enzymes  
INVENTOR(S): Stevens, Rodney W.; Nasami, Nakane  
PATENT ASSIGNEE(S): Pfizer Inc., USA  
SOURCE: Eur. Pat. Appl., 19 pp.  
CODEN: EPXIXW  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 419210	A1	19910327	EP 1990-310199	19900918 <-
EP 419210	B1	19941102		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 03109378	A	19910509	JP 1989-246732	19890922 <-
JP 06000759	B	19940105		
US 5141950	A	19920825	US 1990-563264	19900914 <-
AT 113586	T	19941115	AT 1990-310199	19900918 <-
ES 2062395	T3	19941216	ES 1990-310199	19900918 <-
CA 2025849	A1	19910323	CA 1990-2025849	19900920 <-
PRIORITY APPL. INFO.:			JP 1989-246732	A 19890922 <-

OTHER SOURCE(S): MARPAT 115:49687  
IT 134869-16-2P 134869-17-3P 134869-18-4P  
134869-19-5P 134869-20-6P 134869-21-9P  
134869-22-0P 134869-25-3P 134869-26-4P  
RL: SPN (Synthetic preparation); PRFP (Preparation)  
(preparation of, as lipoxigenase and cyclooxygenase inhibitor)  
RN 134869-16-2 CAPLUS  
CN 1H-Benzimidazole-2,6-diamine, N2-phenyl-N6-(phenylmethyl)-, hydrochloride  
(1:2) (CA INDEX NAME)




●2 HCl

RN 134869-17-3 CAPLUS  
CN 1H-Benzimidazole-2,6-diamine, N2-(3-methylphenyl)-N6-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 134869-18-4 CAPLUS  
CN 1H-Benzimidazole-2,6-diamine, N2-(2-methylphenyl)-N6-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 134869-19-5 CAPLUS  
CN 1H-Benzimidazole-2,6-diamine, N2-(4-methylphenyl)-N6-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 134869-20-8 CAPLUS  
CN 1H-Benzimidazole-2,6-diamine, N2-(4-butylphenyl)-N6-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 134869-21-9 CAPLUS  
CN 1H-Benzimidazole-2,6-diamine, N2-1-naphthalenyl-N6-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 134869-22-0 CAPLUS  
CN 1H-Benzimidazole-2,6-diamine, N6-(phenylmethyl)-N2-3-pyridinyl-, hydrochloride (1:3) (CA INDEX NAME)




●3 HCl

RN 134869-25-3 CAPLUS  
CN 1H-Benzimidazole-2,6-diamine, N2-(3-methoxyphenyl)-N6-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 134869-26-4 CAPLUS  
CN 1H-Benzimidazole-2,6-diamine, N2-methyl-N2-phenyl-N6-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

IT 134869-39-9  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(reductive benzylation of, by benzaldehyde)  
RN 134869-39-9 CAPLUS  
CN 1H-Benzimidazole-2,6-diamine, N2-phenyl- (CA INDEX NAME)




OS.CITING REF COUNT: 18 THERE ARE 18 CAPLUS RECORDS THAT CITE THIS RECORD (24 CITINGS)

15 ANSWER 21 OF 36 CAPLUS COPYRIGHT 2009 ACS ON STN  
ACCESSION NUMBER: 1990:478244 CAPLUS <LOSIND:20091110>  
DOCUMENT NUMBER: 114:81830  
ORIGINAL REFERENCE NO.: 114:13976h,13977a  
TITLE: Preparation of benzimidazole derivatives and analogs as antiulcer and cardiovascular agents  
INVENTOR(S): Bru-Maglier, Nicole; Gungor, Timur; Lacrazpe, Jean; Launay, Michele; Teulon, Jean Marie  
PATENT ASSIGNEE(S): Laboratoires U.P.S.A., Fr.  
SOURCE: Eur. Pat. Appl., 70 pp.  
CODEN: BFXMXX

DOCUMENT TYPE: Patent  
LANGUAGE: French  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 365850	A2	19900905	EP 1990-400537	19900227 <--
EP 365850	A3	19901219		
R: AT, BE, DE, CH, DE, DK, ES, FR, GB, GR, IT, LL, LU, NL, SE				
FR 2643903	A1	19900907	FR 1989-2833	19890303 <--
CA 2011222	A1	19900903	CA 1990-2011222	19900301 <--
AU 9050611	A	19900906	AU 1990-50611	19900302 <--
ZA 901602	A	19901228	ZA 1990-1602	19900302 <--
JP 03014579	A	19910123	JP 1990-52567	19900303 <--
PRIORITY APPL. INFO.: CASREACT 114:81830; MARPAT 114:81830				A 19900303 <--
OTHER SOURCE(S):				
IT 131884-91-9P				
RL: SWH (Synthetic preparation); PREP (Preparation) (preparation of, as antiulcer and cardiovascular agent)				
RN 131884-91-9 CAPLUS				
CN 1H-Benzimidazol-2-amine, 6-(1H-imidazol-1-yl)-N-4-pyridinyl- (CA INDEX NAME)				




OS.CITING REF COUNT: 17 THERE ARE 17 CAPLUS RECORDS THAT CITE THIS RECORD (24 CITINGS)

15 ANSWER 22 OF 36 CAPLUS COPYRIGHT 2009 ACS ON STN  
ACCESSION NUMBER: 1990:478244 CAPLUS <LOSIND:20091110>  
DOCUMENT NUMBER: 113:78244  
ORIGINAL REFERENCE NO.: 113:13239a,13242a  
TITLE: Diheterocyclic compounds from dithiocarbamates and derivatives thereof. I.  
2,2'-(Arylenediamino)bisbenzoxazoles,  
2,2'-(arylenediamino)bis(imidazopyridines) and  
8,8'-(arylenediamino)bispyridines  
AUTHOR(S): Garin, Javier; Melendez, Enrique; Marchan, Francisco L.; Merino, Pedro; Orduna, Jesus; Tejedor, Rosa; Tejero, Tomas  
CORPORATE SOURCE: Inst. Cienc. Mater. Aragon, Univ. Zaragoza, Zaragoza, E-50009, Spain  
SOURCE: Journal of Heterocyclic Chemistry (1990), 27(2), 221-6  
CODEN: JHCCAD; ISSN: 0022-152X  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 113:78244  
IT 128587-22-4P 128587-27-9P  
RL: SWH (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 128587-22-4 CAPLUS  
CN 1,4-bis(2-amino-1H-imidazol-1-yl)-N,N'-bis(6-nitro-1H-benzimidazol-2-yl)- (CA INDEX NAME)






RN 128587-27-9 CAPLUS  
CN 1,4-Benzenediamine, 2-methyl-N1,N4-bis(6-nitro-1H-benzimidazol-2-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

LS ANSWER 23 OF 36 CAPLUS COPYRIGHT 2009 ACS on SW  
ACCESSION NUMBER: 1988:632046 CAPLUS <<LOGINDID::20091110>>  
DOCUMENT NUMBER: 109:232046  
ORIGINAL REFERENCE NO.: 109:38399a,38402a  
TITLE:  
Antioxidative efficiency of substituted N-phenyl  
N-pyrazolyl-3, N-phenyl N-benzimidazolyl-2, and  
N-berthiazolyl-2 N-benzimidazolyl-2 amines in the  
thermooxidation of polypropylene  
AUTHOR(S):  
CORPORATE SOURCE: Matisova-Rychla, L.; Rychly, J.; Neske, M.; Schulz, M.  
Cent. Chem. Res., Slovak Acad. Sci., Bratislava, 842  
36, Czech.  
SOURCE: Polymer Degradation and Stability (1988),  
21(4), 323-33  
CODEN: PIDSTW; ISSN: 0141-3910  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 84601-36-7  
RL: UNES (Uses)

(antioxidative efficiency of, in thermooxidn. of isotactic  
polypropylene)  
RN 84601-36-7 CAPLUS  
CN 1H-Benzimidazol-2-amine, N-(4-methoxyphenyl)-6-nitro- (CA INDEX NAME)




OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

LS ANSWER 24 OF 36 CAPLUS COPYRIGHT 2009 ACS on SW  
ACCESSION NUMBER: 1983:539933 CAPLUS <<LOGINDID::20091110>>  
DOCUMENT NUMBER: 95:139933  
ORIGINAL REFERENCE NO.: 95:21501a,21504a  
TITLE: Heterocyclic diarylamine derivatives  
INVENTOR(S): Serban, Alexander; Watson, Keith G.; Barton, John E.  
D.  
PATENT ASSIGNED(S): ICI Australia Ltd., Australia  
SOURCE: Can., 65 pp.  
CODEN: CAXX44  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. WDM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 1145344	A1	19830426	CA 1980-347768	19800317 <--
AU 8055985	A	19800925	AU 1980-55985	19790319 <--
AU 53493	B2	19840105		
ZA 8001246	A	19810325	ZA 1980-1246	19800304 <--
HU 25187	A2	19830628	HU 1980-603	19800314 <--
HU 183116	B	19840428		

PRIORITY APPL. INFO.: AU 1979-8094 A 19790319 <--  
GB 1979-10365 A 19790412 <--  
AU 1979-8886 A 19790522 <--

IT 77206-07-6P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPW (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(preparation and herbicidal activity of)  
RN 77206-07-6 CAPLUS  
CK Propanoic acid, 2-[4-[methyl(6-nitro-1H-benzimidazol-2-yl)amino]phenoxy]-, methyl ester (CA INDEX NAME)



LS ANSWER 25 OF 36 CAPLUS COPYRIGHT 2009 ACS on SW  
ACCESSION NUMBER: 1983:470623 CAPLUS <<LOGINDID::20091110>>  
DOCUMENT NUMBER: 95:70625  
ORIGINAL REFERENCE NO.: 95:10567a,10970a  
TITLE: A facile synthesis of dimethyl  
N-aryldithiocarbonimidates and  
2-arylamino-benzimidazoles  
AUTHOR(S):  
CORPORATE SOURCE: Dep. Quim. Org., Univ. Zaragoza, Zaragoza, Spain  
SOURCE: Synthesis (1983), (5), 375-6  
CODEN: SYNTRE; ISSN: 0039-7881


Nc1nc2cc(N)ccc2n1Cc1ccc(NC2=CNC3=CC=C(C=C3)C(=O)O)cc1COc1ccc(NC2=NC3=CC(=CC=C3C=C2)C(=O)O1)cc1CN1C=NC2=C1C=CC=C2C(=O)Nc3cc(C)c(Cl)cc3

15 ANSWER 26 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1981:156918 CAPLUS <<LOGINID::20091110>>  
DOCUMENT NUMBER: 94:156918

ORIGINAL REFERENCE NO.: 9425657a,25656a  
TITLE: Hereticidal diarylamine derivatives  
INVENTOR(S): Barton, John Edward Duncan; Serban, Alexander; Watson, Keith Geoffrey  
PATENT ASSIGNEE(S): ICI Australia Ltd., Australia  
SOURCE: Eur. Pat. Appl., 75 pp.  
CODEN: SPXNDW  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KLMD	DATE	APPLICATION NO.	DATE
EP 18080	A1	19801029	EP 1980-300793	19800314 <
EP 18080	B1	19840314		
R: BR, CH, DE, FR, GB, IT, LU				
AU 8055585	A	19800925	AU 1980-55985	19790319 <
AU 534903	B2	19840315		
ZA 8001246	A	19810305	ZA 1980-1246	19800304 <
IL 59533	A	19803131	IL 1980-59533	19800305 <
HU 25187	A2	19830628	HU 1980-603	19800314 <
US 183116	B	19840428		
US 4314065	A	19820202	US 1980-431389	19800317 <
BR 8001618	A	19801118	BR 1980-1618	19800318 <
JP 35149263	A	19801120	JP 1980-33480	19800318 <
JP 40428701	B	19920515		
EP 1879-8094	A	1979-8094		19790319 <
GB 1979-13065	A	1979-13065		19790412 <
AU 1979-8886	A	1979-8886		19790522 <

OTHER SOURCE(S): CASREACT 04156913  
 IL 77206-07-4P  
 RU 77206-07-6 (Biological activity or effector, except adverse); 3SU (Biological study, unclassified); 3SN (Synthetic preparation); 3UO (Biological study); 3PEP (Preparation)  
 (preparation and herbicidal activity of)  
 RU 77206-07-6 CAPLMS  
 CN Propionic acid, 2-[4-[methyl(6-nitro-1H-benzimidazol-2-yl)amino]phenoxy]-, methyl ester (CA INDEX NAME)




OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD  
(4 CITINGS)

LS ANSWER 27 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1973:58423 CAPLUS <LOGINID:20091110>  
DOCUMENT NUMBER: 75:58423  
ORIGINAL REFERENCE NO.: 78:9271a, 9274a  
TITLE: Arthelmintic isothiocyanatobenzoazoles,  
benzimidazoles, and -benzoxazoles  
INVENTOR(S): Breznieser, Paul; Wenger, Thomas; Gallay, Jean  
Jacques; Schmid, Wolfgang  
PATENT ASSIGNEE(S): Ciba-Geigy A.-G.


SOURCE: Ger. Offen., 46 pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NTH. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2225071	A	19721207	DE 1972-2225071	19720523 <-
US 3840550	A	19741008	US 1972-255334	19720522 <-
BE 783791	A1	19721123	BE 1972-117737	19720523 <-
NL 7265929	A	19721128	NL 1972-6929	19720523 <-
FR 2138884	A1	19750105	FR 1972-18265	19720523 <-
ZA 7203514	A	19750328	ZA 1972-3514	19720523 <-
DD 89517	A5	19750620	DD 1972-163138	19720523 <-
US 3894037	A	19750708	US 1974-491585	19740724 <-
US 3933841	A	19760120	US 1974-491584	19740724 <-
PRIORITY APPLN. INFO.:			CH 1971-7542	A 19710524 <-
			US 1972-255334	A3 19720522 <-
			US 1974-255334	A3 19740522 <-

IT 39223-75-1P 39480-77-8P  
 RI: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 39223-75-1 CAPLUS  
 CN 1H-Benzimidazol-2-amine, 6-isothiocyanato-N-(4-methoxyphenyl)- (CA INDEX NAME)



RN 39480-77-8 CAPLUS  
 CN 1H-Benzimidazol-2-amine, N-(4-chlorophenyl)-6-isothiocyanato-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

GS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)


15 ANSWER 28 OF 36 CAPLUS COPYRIGHT 2009 ACS ON STN  
 ACCESSION NUMBER: 1964:418220 CAPLUS <LOGINID:20091110>  
 DOCUMENT NUMBER: 61:18220  
 ORIGINAL REFERENCE NO.: 61:3091d-f

TITLE: Carbonimidoyl dihalides as organic intermediates. I.  
 The preparation of 2-arylamino benzimidazoles  
 AUTHOR(S): Murphy, Daniel B.  
 CORPORATE SOURCE: City Univ. of New York, New York, NY  
 SOURCE: Journal of Organic Chemistry (1964), 29(6), 1613-15  
 CODEN: JOCRAH; ISSN: 0022-3263


DOCUMENT TYPE: Journal  
 LANGUAGE: Unavailable  
 OTHER SOURCE(S): CASREACT 61:18220  
 IT 86601-34-3P, Benzimidazole, 2-anilino-5(or 6)-nitro-  
 97027-41-3P, Benzimidazole, 2-anilino-5-chloro-7-nitro-(?)  
 97028-28-9P, Benzimidazole,  
 6-chloro-2-(p-chloroanilino)-4-nitro-(?)  
 RI: PREP (Preparation)  
 (preparation of)  
 RN 86601-34-5 CAPLUS  
 CN 1H-Benzimidazol-2-amine, 6-nitro-N-phenyl- (CA INDEX NAME)



RN 97027-41-3 CAPLUS  
 CN 1H-Benzimidazol-2-amine, 5-chloro-7-nitro-N-phenyl- (CA INDEX NAME)



RN 97028-28-9 CAPLUS  
 CN 1H-Benzimidazol-2-amine, 5-chloro-N-(4-chlorophenyl)-7-nitro- (CA INDEX NAME)




GS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

15 ANSWER 29 OF 36 CAPLUS COPYRIGHT 2009 ACS ON STN  
 ACCESSION NUMBER: 1962:13033 CAPLUS  
 DOCUMENT NUMBER: 56:13033  
 ORIGINAL REFERENCE NO.: 56:2457a-b


TITLE: Compounds containing both cyclic amidine and alkylene rings  
 INVENTOR(S): Shen, Kwan Ting  
 PATENT ASSIGNER(S): Petrolite Corp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Unavailable  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2987522		19610606	US 1958-721643	19580317 <--
IT 96170-15-9	96971-20-9	98422-81-2		
100628-77-1	101320-03-0	102345-66-4		
107541-46-8				

(Derived from data in the 7th Collective Formula Index (1962-1966))  
 RN 96170-15-9 CAPLUS  
 CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)ethylamino]-N,N-diethyl-5-nitro- (CA INDEX NAME)




RN 96971-20-9 CAPLUS  
 CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)(phenylethyl)amino]-N,N-diethyl-5-nitro-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 98422-81-2 CAPLUS  
 CN Glycine, N-[1-[2-(diethylamino)ethyl]-5-nitro-2-benzimidazolyl]-N-(p-ethoxyphenyl)-, ethyl ester (7CI) (CA INDEX NAME)




RN 100628-77-1 CAPLUS  
 CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)ethylamino]-N,N-diethyl-5-nitro-, hydrochloride (1:1) (CA INDEX NAME)




● X HCl

RN 101320-03-0 CAPLUS  
 CN 2-Benzimidazolecarboxylic acid, 1-[2-(diethylamino)ethyl]-N-(p-ethoxyphenyl)-5-nitro-, ethyl ester, hydrochloride (7CI) (CA INDEX NAME)



● X HCl


RN 102345-66-4 CAPLUS  
 CN Benzamide, N-[1-[2-(diethylamino)ethyl]-5-nitro-1H-benzimidazol-2-yl]-N-(4-ethoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 107541-46-8 CAPLUS

CN Glycine, N-[1-[2-(diethylamino)ethyl]-5-nitro-2-benzimidazolyl]-N-(p-ethoxyphenyl)-, ethyl ester, hydrochloride (7CI) (CA INDEX NAME)




● HCl

IT 101548-62-3P, p-Propionophenetide,  
N-[1-[2-(diethylamino)ethyl]-5-nitro-2-benzimidazolyl]-  
101548-63-4P, p-Propionophenetide,  
N-[1-[2-(diethylamino)ethyl]-5-nitro-2-benzimidazolyl]-, hydrochloride  
RL: PREP (Preparation)  
(preparation of)


RN 101548-62-3 CAPLUS

CN Propanamide, N-[1-[2-(diethylamino)ethyl]-5-nitro-1H-benzimidazol-2-yl]-N-(4-ethoxyphenyl)- (CA INDEX NAME)



RN 101548-63-4 CAPLUS

CN Propanamide, N-[1-[2-(diethylamino)ethyl]-5-nitro-1H-benzimidazol-2-yl]-N-(4-ethoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)



● X HCl

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

15 ANSWER 30 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1962:13032 CAPLUS

DOCUMENT NUMBER: 56:13032

ORIGINAL REFERENCE NO.: 56:24551,2456a-1,2457a

TITLE: Benzimidazoles

INVENTOR(S): Hoffmann, Karl; Hunger, Alfred; Kehrle, Gindrich; Rossi, Alberto

PATENT ASSIGNEE(S): Ciba Pharmaceutical Products, Inc.

DOCUMENT TYPE: Patent

LANGUAGE: Unavailable

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3000898		19580919	US	<--
GB 928154			GB	
PRIORITY APPLN. INFO.:			CH	19590831 <--


IT 94916-17-3P, Benzimidazole,  
2-anilino-1-[2-(diethylamino)ethyl]-5-nitro- 94916-20-8P,  
Benzimidazole, 1-[2-(diethylamino)ethyl]-5-nitro-2-p-phenetidin-  
95128-90-8P, Benzimidazole,  
1-[2-(diethylamino)ethyl]-2-[N-(p-methoxyphenyl)acetamido]-5-nitro-  
95698-89-8P, Benzimidazole,  
2-[N-(p-ethoxyphenyl)acetamido]-5-nitro-1-(2-piperidinoethyl)-  
95167-31-8P, Benzimidazole,  
1-[2-(diethylamino)ethyl]-2-[N-(p-ethoxyphenyl)acetamido]-5-nitro-  
95167-54-3P, Benzimidazole,  
1-[2-(diethylamino)ethyl]-5-nitro-2-p-phenetidin- 95170-15-8P  
Benzimidazole, 1-[2-(diethylamino)ethyl]-2-[N-ethyl-p-phenetidin-5-  
nitro- 95393-87-4P, Benzimidazole,  
1-[2-(diethylamino)ethyl]-2-[N-(p-ethoxyphenyl)acetamido]-5-nitro-  
95971-20-9P, Benzimidazole,  
2-[N-benzyl-p-phenetidin-1-[2-(diethylamino)ethyl]-5-nitro-  
dihydrochloride 97237-44-4P, Benzimidazole,  
5-nitro-2-p-phenetidin-1-(2-piperidinoethyl)- 97297-45-5P,  
Propionamide, N-[1-[2-(diethylamino)ethyl]-5-nitro-2-benzimidazolyl]-  
98422-81-2P, Glycine, N-[1-[2-(diethylamino)ethyl]-5-nitro-2-  
benzimidazolyl]-N-(p-ethoxyphenyl)-, ethyl ester 100176-34-9P,  
Benzimidazole, 1-[2-(diethylamino)ethyl]-5-nitro-2-p-phenetidin-  
hydrochloride 100260-95-5P, Benzimidazole,  
2-anilino-1-[2-(diethylamino)ethyl]-5-nitro-, hydrochloride

100433-67-8F, Benzimidazole,  
1-[2-(diethylamino)ethyl]-5-nitro-2-(N-phenylacetamido)-, hydrochloride  
100628-46-4F, Benzimidazole,  
1-[2-(dimethylamino)ethyl]-2-[N-(p-ethoxyphenyl)acetamido]-5-nitro-  
hydrochloride 100628-59-9F, Benzimidazole,  
1-[2-(diethylamino)ethyl]-5-nitro-2-p-phenetidin-<sub>o</sub>, hydrochloride  
100628-77-1F, Benzimidazole,  
1-[2-(diethylamino)ethyl]-2-(N-ethyl-p-phenetidin-<sub>o</sub>)-5-nitro-  
hydrochloride 101016-59-5F, Benzimidazole,  
1-[2-(diethylamino)ethyl]-2-[N-(p-ethoxyphenyl)acetamido]-5-nitro-  
hydrochloride 101320-03-0F, 2-Benzimidazolecarboxylic acid,  
1-[2-(diethylamino)ethyl]-N-(p-ethoxyphenyl)-5-nitro, ethyl ester,  
hydrochloride 101548-62-3F, p-Propionophenethide,  
N-[1-[2-(diethylamino)ethyl]-5-nitro-2-benzimidazolyl]-  
101548-63-4F, p-Propionophenethide,  
N-[1-[2-(diethylamino)ethyl]-5-nitro-2-benzimidazolyl]-, hydrochloride  
102345-66-4F, Benzimidazole,  
1-[2-(diethylamino)ethyl]-2-[N-(p-ethoxyphenyl)benzanido]-5-nitro-  
hydrochloride 104352-29-6F, Benzimidazole,  
1-[2-(diethylamino)ethyl]-2-[N-(p-methoxyphenyl)acetamido]-5-nitro-  
hydrochloride 104763-43-1F, p-Formophenethide,  
N-[1-[2-(diethylamino)ethyl]-5-nitro-2-benzimidazolyl]-  
104763-44-2F, p-Formophenethide,  
N-[1-[2-(diethylamino)ethyl]-5-nitro-2-benzimidazolyl]-, hydrochloride  
104763-51-1F, Propionanilide,  
N-[1-[2-(diethylamino)ethyl]-5-nitro-2-benzimidazolyl]-, hydrochloride  
104763-77-1F, Benzimidazole,  
5-nitro-2-p-phenetidin-<sub>o</sub>-1-(2-piperidin-<sub>o</sub>thyl)-, hydrochloride  
107541-46-8F, Glycine, N-[1-[2-(diethylamino)ethyl]-5-nitro-2-  
benzimidazolyl]-N-(p-ethoxyphenyl)-, ethyl ester, hydrochloride  
875832-28-3F, Benzimidazole,  
2-p-anisidino-1-[2-(diethylamino)ethyl]-5-nitro- 879654-71-4F,  
Benzimidazole, 2-p-anisidino-1-[2-(diethylamino)ethyl]-5-nitro-  
hydrochloride  
RL: PRF (Preparation)  
(preparation of)


RN 94316-17-3 CAPLUS  
CN 1H-Benzimidazole-1-ethanamine, N,N-diethyl-5-nitro-2-(phenylamino)- (CA INDEX NAME)




RN 94316-20-8 CAPLUS  
CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)amino]-N,N-dimethyl-5-nitro- (CA INDEX NAME)




RN 95128-90-8 CAPLUS  
CN Acetamide, N-[1-[2-(diethylamino)ethyl]-5-nitro-1H-benzimidazol-2-yl]-N-(4-methoxyphenyl)- (CA INDEX NAME)




RN 95698-89-8 CAPLUS  
CN Acetamide, N-[4-(ethoxyphenyl)-N-[5-nitro-1-[2-(1-piperidinyl)ethyl]-1H-benzimidazol-2-yl]- (CA INDEX NAME)




RN 96167-31-6 CAPLUS  
CN Acetamide, N-[1-[2-(dimethylamino)ethyl]-5-nitro-1H-benzimidazol-2-yl]-N-(4-ethoxyphenyl)- (CA INDEX NAME)




RN 96167-54-3 CAPLUS  
CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)amino]-N,N-diethyl-5-nitro- (CA INDEX NAME)




RN 96170-15-9 CAFLUS  
CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)ethylamino]-N,N-diethyl-5-nitro- (CA INDEX NAME)



RN 96309-87-4 CAFLUS  
CN Acetamide, N-[1-[2-(diethylamino)ethyl]-5-nitro-1H-benzimidazol-2-yl]-N-(4-ethoxyphenyl)- (CA INDEX NAME)





RN 96971-20-9 CAFLUS  
CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)(phenylethyl)amino]-N,N-diethyl-5-nitro-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl


RN 97297-44-4 CAFLUS  
CN 1H-Benzimidazol-2-amine, N-(4-ethoxyphenyl)-5-nitro-1-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)




RN 97297-45-5 CAFLUS  
CN Propanamide, N-[1-[2-(diethylamino)ethyl]-5-nitro-1H-benzimidazol-2-yl]-N-phenyl- (CA INDEX NAME)



RN 98422-81-2 CAFLUS  
CN Glycine, N-[1-[2-(diethylamino)ethyl]-5-nitro-2-benzimidazolyl]-N-(p-ethoxyphenyl)-, ethyl ester (7Cl) (CA INDEX NAME)




RN 100176-34-9 CAFLUS  
CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)amino]-N,N-dimethyl-5-nitro-, hydrochloride (1:?) (CA INDEX NAME)



● N HCl

RN 100260-95-5 CAPLUS


CN 1H-Benzimidazole-1-ethanamine, N,N-diethyl-5-nitro-2-(phenylamino)-, hydrochloride (1:?) (CA INDEX NAME)



●X HCl

RN 100433-67-9 CAPLUS


CN Acetamide, N-[1-[2-(diethylamino)ethyl]-5-nitro-1H-benzimidazol-2-yl]-N-phenyl-, hydrochloride (1:?) (CA INDEX NAME)



●X HCl

RN 100628-46-4 CAPLUS


CN Acetamide, N-[1-[2-(dimethylamino)ethyl]-5-nitro-1H-benzimidazol-2-yl]-N-(4-ethoxyphenyl)-, hydrochloride (1:?) (CA INDEX NAME)



●X HCl

RN 100628-59-9 CAPLUS


CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)amino]-N,N-diethyl-5-nitro-, hydrochloride (1:?) (CA INDEX NAME)



●X HCl

RN 100628-77-1 CAPLUS


CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)ethylamino]-N,N-diethyl-5-nitro-, hydrochloride (1:?) (CA INDEX NAME)



●X HCl

RN 101016-53-5 CAPLUS

CN Acetamide, N-[1-[2-(diethylamino)ethyl]-5-nitro-1H-benzimidazol-2-yl]-N-(4-ethoxyphenyl)-, hydrochloride (1:?) (CA INDEX NAME)




●X HCl

RN 101320-03-0 CAPLUS


CN 2-Benzimidazolecarboxamic acid, 1-[2-(diethylamino)ethyl]-N-(p-ethoxyphenyl)-5-nitro-, ethyl ester, hydrochloride (7CI) (CA INDEX NAME)






● X HCl

RN 101548-62-3 CASUS  
CN Propanamide, N-[1-[2-(diethylamino)ethyl]-5-nitro-1H-benzimidazol-2-yl]-N-(4-ethoxyphenyl)- (CA INDEX NAME)




RN 101548-63-4 CASUS  
CN Propanamide, N-[1-[2-(diethylamino)ethyl]-5-nitro-1H-benzimidazol-2-yl]-N-(4-ethoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)




● X HCl

RN 102345-66-4 CASUS  
CN Benzamide, N-[1-[2-(diethylamino)ethyl]-5-nitro-1H-benzimidazol-2-yl]-N-(4-ethoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 104352-23-6 CASUS  
CN Acetamide, N-[1-[2-(diethylamino)ethyl]-5-nitro-1H-benzimidazol-2-yl]-N-(4-methoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 104763-43-1 CASUS  
CN Formamide, N-[1-[2-(diethylamino)ethyl]-5-nitro-1H-benzimidazol-2-yl]-N-(4-ethoxyphenyl)- (CA INDEX NAME)




RN 104763-44-2 CASUS  
CN Formamide, N-[1-[2-(diethylamino)ethyl]-5-nitro-1H-benzimidazol-2-yl]-N-(4-ethoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)





● HCl

RN 104763-51-1 CAPLUS  
CN Proparandim, N-[1-(2-(diethylamino)ethyl)-5-nitro-1H-benzimidazol-2-yl]-N-phenyl-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 104763-77-1 CAPLUS  
CN 1H-Benzimidazol-2-amine, N-(4-ethoxyphenyl)-5-nitro-1-[2-(1-piperidinylethyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 107541-46-8 CAPLUS  
CN Glycine, N-[1-(2-(diethylamino)ethyl)-5-nitro-2-benzimidazolyl]-N-(p-ethoxyphenyl)-, ethyl ester, hydrochloride (7Cl) (CA INDEX NAME)




● HCl

RN 875832-28-3 CAPLUS  
CN 1H-Benzimidazole-1-ethanamine, N,N-diethyl-2-[(4-methoxyphenyl)amino]-5-nitro- (CA INDEX NAME)



RN 879654-71-4 CAPLUS  
CN 1H-Benzimidazole-1-ethanamine, N,N-diethyl-2-[(4-methoxyphenyl)amino]-5-nitro-, hydrochloride (1:1) (CA INDEX NAME)




● HCl


OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

15 ANSWER 31 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1962:12986 CAPLUS <LOGINID:20091110>  
DOCUMENT NUMBER: 56:12986  
ORIGINAL REFERENCE NO.: 56:2437g-1  
TITLE: N-Acetylated pyrazolones  
AUTHOR(S): Wahlberg, Erik  
CORPORATE SOURCE: Univ. Uppsala, Swed.  
SOURCE: Arkiv for Kemi (1960), 17, 83-8  
CODEN: ARKED; ISSN: 0365-6128



DOCUMENT TYPE: Journal  
 LANGUAGE: Unavailable  
 IT 94916-20-8 96167-54-3 97297-44-4  
 100176-34-9 100628-59-9 104763-77-1  
 (Derived from data in the 7th Collective Formula Index (1962-1966))  
 RN 94916-20-8 CAPLUS  
 CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)amino]-N,N-dimethyl-5-nitro- (CA INDEX NAME)




RN 96167-54-3 CAPLUS  
 CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)amino]-N,N-diethyl-5-nitro- (CA INDEX NAME)



RN 97297-44-4 CAPLUS  
 CN 1H-Benzimidazol-2-amine, N-(4-ethoxyphenyl)-5-nitro-1-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)




RN 100176-34-9 CAPLUS  
 CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)amino]-N,N-dimethyl-5-nitro-, hydrochloride (1:1) (CA INDEX NAME)





● N HCl

RN 100628-59-9 CAPLUS  
 CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)amino]-N,N-diethyl-5-nitro-, hydrochloride (1:1) (CA INDEX NAME)



● N HCl

RN 104763-77-1 CAPLUS  
 CN 1H-Benzimidazol-2-amine, N-(4-ethoxyphenyl)-5-nitro-1-[2-(1-piperidinyl)ethyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

L5 ANSWER 32 OF 36 CAPLUS COPYRIGHT 2009 ACS on STM  
 ACCESSION NUMBER: 1962:12985 CAPLUS <LOGINID:20091110>  
 DOCUMENT NUMBER: 56:12985  
 ORIGINAL REFERENCE NO.: 56:2436h-1,2437a-g


TITLE: Benzimidazole and related heterocycles. VII. New 2-aminobenzimidazoles  
 AUTHOR(S): Runger, A.; Kehrle, J.; Rossi, A.; Hoffmann, K.  
 CORPORATE SOURCE: CIBA A.-G., Basel, Switz.  
 SOURCE: Helvetica Chimica Acta (1961), 44, 1273-82  
 CODEN: HCACAV; ISSN: 0018-019X  
 DOCUMENT TYPE: Journal  
 LANGUAGE: German  
 OTHER SOURCE(S): CASREACT 56:1295

IT 94916-17-3F, Benzimidazole,  
 2-anilino-1-[2-(diethylamino)ethyl]-5-nitro- 94916-20-8F,  
 Benzimidazole, 1-[2-(dimethylamino)ethyl]-5-nitro-2-p-phenetidin-  
 96167-54-3F, Benzimidazole,  
 1-[2-(diethylamino)ethyl]-5-nitro-2-p-phenetidin- 97297-44-4F  
 , Benzimidazole, 5-nitro-2-p-phenetidin-1-(2-piperidinoethyl)-  
 100176-34-9F, Benzimidazole,  
 1-[2-(dimethylamino)ethyl]-5-nitro-2-p-phenetidin-, hydrochloride  
 100260-95-5F, Benzimidazole,  
 2-anilino-1-[2-(diethylamino)ethyl]-5-nitro-, hydrochloride  
 100628-59-9F, Benzimidazole,  
 1-[2-(diethylamino)ethyl]-5-nitro-2-p-phenetidin-, hydrochloride  
 104763-77-1F, Benzimidazole,  
 5-nitro-2-p-phenetidin-1-(2-piperidinoethyl)-, hydrochloride  
 875832-28-3F, Benzimidazole,  
 2-p-anisidino-1-[2-(diethylamino)ethyl]-5-nitro- 879654-71-4F,  
 Benzimidazole, 2-p-anisidino-1-[2-(diethylamino)ethyl]-5-nitro-,  
 hydrochloride  
 RI: PREP (Preparation)  
 (preparation of)


RM 94916-17-3 CAPLUS  
 CN 1H-Benzimidazole-1-ethanamine, N,N-diethyl-5-nitro-2-(phenylamino)- (CA INDEX NAME)





RM 94916-20-8 CAPLUS  
 CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)amino]-N,N-dimethyl-5-nitro- (CA INDEX NAME)




RM 96167-54-3 CAPLUS  
 CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)amino]-N,N-diethyl-5-nitro- (CA INDEX NAME)



RM 97297-44-4 CAPLUS  
 CN 1H-Benzimidazole-2-amine, N-(4-ethoxyphenyl)-5-nitro-1-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)




RM 100176-34-9 CAPLUS  
 CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)amino]-N,N-dimethyl-5-nitro-, hydrochloride (1:?) (CA INDEX NAME)




●: HCl

RM 100260-95-5 CAPLUS  
 CN 1H-Benzimidazole-1-ethanamine, N,N-diethyl-5-nitro-2-(phenylamino)-, hydrochloride (1:?) (CA INDEX NAME)




● R EC1

RN 100628-59-9 CAPLUS  
CN 1H-Benzimidazole-1-ethanamine, 2-[(4-ethoxyphenyl)amino]-N,N-diethyl-5-nitro-, hydrochloride (1:1) (CA INDEX NAME)




● R EC1

RN 104763-77-1 CAPLUS  
CN 1H-Benzimidazol-2-amine, N-(4-ethoxyphenyl)-5-nitro-1-[2-(1-piperidinylethyl)-], hydrochloride (1:1) (CA INDEX NAME)




● EC1

RN 875832-28-3 CAPLUS  
CN 1H-Benzimidazole-1-ethanamine, N,N-diethyl-2-[(4-methoxyphenyl)amino]-5-nitro- (CA INDEX NAME)




RN 879654-71-4 CAPLUS  
CN 1H-Benzimidazole-1-ethanamine, N,N-diethyl-2-[(4-methoxyphenyl)amino]-5-nitro-, hydrochloride (1:1) (CA INDEX NAME)



● EC1

OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)


L5 ANSWER 33 OF 36 CAPLUS COPYRIGHT 2009 ACS ON STN  
ACCESSION NUMBER: 1953:51359 CAPLUS <<LOGINID:20091110>>  
DOCUMENT NUMBER: 47:51359  
ORIGINAL REFERENCE NO.: 47:8669b-1,8670a-e  
TITLE: Aromatic diazo compounds. VII. Coupling with m-phenylenediamine  
AUTHOR(S): Muzik, Ferdinand; Allan, Zdenek J.  
CORPORATE SOURCE: Chem. Research Inst., Pardubice-Rybitvi, Czech.  
SOURCE: Chemické Listy pro Vedu a Prumysl (1952), 277-80, 350-7  
CODEN: CLPRAN; ISSN: 0366-6832  
DOCUMENT TYPE: Journal  
LANGUAGE: Unavailable  
IT 853788-72-4F, Benzimidazole, 7-acetamido-1-p-chloroanilino-4-(p-chlorophenylazo)-2,6-dimethyl-  
RU: PREP (Preparation) (preparation of)  
RN 853788-72-4 CAPLUS  
CN Acetamide, N-[1-[(4-chlorophenyl)amino]-4-[2-(4-chlorophenyl)diazanyl]-2,6-dimethyl-1H-benzimidazol-7-yl]- (CA INDEX NAME)



15 ANSWER 34 OF 36 CAPLUS COPYRIGHT 2009 ACS on STM  
 ACCESSION NUMBER: 1951143092 CAPLUS  
 DOCUMENT NUMBER: 45143092  
 ORIGINAL REFERENCE NO.: 45:7360f-i,7361a-b,7362a  
 TITLE: Amino derivatives  
 INVENTOR(S): Ackermann, Franz  
 PATENT ASSIGNEE(S): C I B A Ltd.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Unavailable  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2550321		19510424	US 1949-60400	19481116 <--

IT 855835-87-1P, Methanesulfonic acid,  
 [[6-(sulfoethylamino)-2-benzimidazolyl]anilino]-  
 RL: PREP (Preparation)  
 (preparation of)  
 RN 855835-87-1 CAPLUS  
 CN Methanesulfonic acid, 1-[[6-(methylsulfoamino)-1H-benzimidazol-2-yl]phenylamino]- (CA INDEX NAME)




15 ANSWER 35 OF 36 CAPLUS COPYRIGHT 2009 ACS on STM  
 ACCESSION NUMBER: 194412159 CAPLUS <LOGINTD:20091110>  
 DOCUMENT NUMBER: 1812159  
 ORIGINAL REFERENCE NO.: 18:1652d-i,1653a-g  
 TITLE: Constitution of the reaction products from o-aminoazo


compounds and aldehydes. II  
 AUTHOR(S): Fischer, Otto  
 SOURCE: Journal fuer Praktische Chemie (Leipzig) (1924), 107, 16-49  
 CODEN: JPCBAQ; ISSN: 0021-9383  
 DOCUMENT TYPE: Journal  
 LANGUAGE: Unavailable  
 IT 861783-92-8, Benzimidazole, 5-amino-1-anilino-2-phenyl- (and derivs.)  
 RN 861783-92-8 CAPLUS  
 CN 1H-Benzimidazole-1,5-diamine, N1,2-diphenyl- (CA INDEX NAME)




IT 861293-79-0P, Benzimidazole,  
 1-(N-nitrosoanilino)-5-salicylamino-2-salicyl- 861305-30-8P,  
 Benzimidazole, 1-anilino-5-salicylamino-2-salicyl-  
 861305-32-0P, Benzimidazole, 1-anilino-5-benzalamino-2-phenyl-  
 861783-94-0P, Benzimidazole,  
 5-acetamido-1-(N-acetylanylino)-2-phenyl- 861800-49-9P,  
 Benzimidazole, 5-benzalamino-1-(N-nitrosoanilino)-2-phenyl-  
 RL: PREP (Preparation)  
 (preparation of)  
 RN 861293-79-0 CAPLUS  
 CN Phenol, 2-[[[5-[[[2-hydroxyphenyl)methylene]amino]-1-(nitrosophenylamino)-1H-benzimidazol-2-yl]methyl]- (CA INDEX NAME)




RN 861305-30-8 CAPLUS  
 CN Phenol, 2-[[[5-[[[2-hydroxyphenyl)methylene]amino]-1-(phenylamino)-1H-benzimidazol-2-yl]methyl]- (CA INDEX NAME)




RN 861305-32-0 CAPLUS  
CN 1H-Benzimidazole-1,5-diamine, N1,2-diphenyl-N5-(phenylmethylene)- (CA INDEX NAME)



RN 861793-94-0 CAPLUS  
CN Acetamide, N-[5-(acetylamino)-2-phenyl-1H-benzimidazol-1-yl]-N-phenyl- (CA INDEX NAME)



RN 861800-49-9 CAPLUS  
CN 1H-Benzimidazole-1,5-diamine, N1-nitroso-N1,2-diphenyl-N5-(phenylmethylene)- (CA INDEX NAME)



CS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

15 ANSWER 36 OF 36 CAPLUS COPYRIGHT 2009 ACS ON STN  
ACCESSION NUMBER: 19138050 CAPLUS <<LOGINID::20091110>>

DOCUMENT NUMBER: 718050

ORIGINAL REFERENCE NO.: 7:11840-4,1185-a

TITLE: Substituted o-Hydroxy-and

o-Methylbenzimidazoles

AUTHOR(S): Wm. G. Ratner, L.

CORPORATE SOURCE: Univ. Zurich

SOURCE: Berichte der Deutschen Chemischen Gesellschaft (

1913), 45, 3238-55

CODEN: BDCGAS; ISSN: 0365-9496

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable


IT 86601-34-5P, Benzimidazole, 2-anilino-5-nitro-

RI: PREP (Preparation)

(preparation of)

RN 86601-34-5 CAPLUS

CN 1H-Benzimidazol-2-amine, 6-nitro-N-phenyl- (CA INDEX NAME)



=> file tsguide

FILES IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter

"HELP COMMANDS" at an arrow prompt (=>).

=> file tsguide

COST IN U.S. DOLLARS

SESSION TOTAL

FULL ESTIMATED COST

ENTRY 150.76 337.34

FILE 'STWGUIDE' ENTERED AT 09:17:46 ON 10 NOV 2009

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Nov 6, 2009 (20091106/DP).

=> log

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/hold:y

(FILE 'HOME' ENTERED AT 09:11:43 ON 10 NOV 2009)

FILE 'REGISTRY' ENTERED AT 09:11:53 ON 10 NOV 2009

L1 STRUCTURE UPLOADED

D

L2 3 SEA FILE=REGISTRY SSS SAM L1

L3 586 SEA FILE=REGISTRY SSS FUL L1

FILE 'CAPLUS' ENTERED AT 09:13:01 ON 10 NOV 2009

L4 51 SEA FILE=CAPLUS SPE=CN ABB=ON FUD=ON L3

L5 36 SEA FILE=CAPLUS SPE=CN ABB=ON FUD=ON L4 AND (PD<20041027 OR

PD<20041027 OR AD<20041027)

D 1-36 1818 HITS\*